1
|
Song WJ, Cheon DH, Song H, Jung D, Chan Park H, Yeong Hwang J, Choi HJ, NamKoong C. Activation of ChAT+ neuron in dorsal motor vagus (DMV) increases blood glucose through the regulation of hepatic gene expression in mice. Brain Res 2024; 1829:148770. [PMID: 38266888 DOI: 10.1016/j.brainres.2024.148770] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/09/2023] [Revised: 01/10/2024] [Accepted: 01/13/2024] [Indexed: 01/26/2024]
Abstract
The brain and peripheral organs communicate through hormones and neural connections. Proper communication is required to maintain normal whole-body energy homeostasis. In addition to endocrine system, from the perspective of neural connections for metabolic homeostasis, the role of the sympathetic nervous system has been extensively studied, but understanding of the parasympathetic nervous system is limited. The liver plays a central role in glucose and lipid metabolism. This study aimed to clarify the innervation of parasympathetic nervous system in the liver and its functional roles in metabolic homeostasis. The liver-specific parasympathetic nervous system innervation (PNS) was shown by tissue clearing, immunofluorescence and transgenic mice at the three-dimensional histological level. The parasympathetic efferent signals were manipulated using a chemogenetic technique and the activation of ChAT+ parasympathetic neurons in dorsal motor vagus (DMV) results in the increased blood glucose through the elevated hepatic gluconeogenic and lipogenic gene expression in the liver. Thus, our study showed the evidence of ChAT+ parasympathetic neurons in the liver and its role for hepatic parasympathetic nervous signaling in glucose homeostasis through the regulation of hepatic gene expression.
Collapse
Affiliation(s)
- Woo-Jin Song
- Functional Neuroanatomy of Metabolism Regulation Laboratory, Department of Anatomy, Division of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Deok-Hyeon Cheon
- Functional Neuroanatomy of Metabolism Regulation Laboratory, Department of Anatomy, Division of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - HeeIn Song
- Functional Neuroanatomy of Metabolism Regulation Laboratory, Department of Anatomy, Division of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Daeun Jung
- Functional Neuroanatomy of Metabolism Regulation Laboratory, Department of Anatomy, Division of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Hae Chan Park
- Functional Neuroanatomy of Metabolism Regulation Laboratory, Department of Anatomy, Division of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Ju Yeong Hwang
- Functional Neuroanatomy of Metabolism Regulation Laboratory, Department of Anatomy, Division of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea
| | - Hyung-Jin Choi
- Functional Neuroanatomy of Metabolism Regulation Laboratory, Department of Anatomy, Division of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea; Department of Biomedical Sciences, Seoul National University College of Medicine, Seoul, Republic of Korea; BK21Plus Biomedical Science Project Team, Seoul National University College of Medicine, Seoul, Republic of Korea; Wide River Institute of Immunology, Seoul National University College of Medicine, Hongchoen, Republic of Korea; Neuroscience Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea.
| | - Cherl NamKoong
- Functional Neuroanatomy of Metabolism Regulation Laboratory, Department of Anatomy, Division of Internal Medicine, Seoul National University College of Medicine, Seoul, Republic of Korea; Neuroscience Research Institute, Seoul National University College of Medicine, Seoul, Republic of Korea; Core Research Laboratory, Medical Science Institute, Kyung Hee University Hospital at Gangdong, Seoul 05278, Republic of Korea.
| |
Collapse
|
2
|
Ding Q, Liu Y, Ju H, Song H, Xiao Y, Liu X, Ren G, Wei D. Reactive cutaneous capillary endothelial proliferation predicted the efficacy of camrelizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma. Med Oral Patol Oral Cir Bucal 2023; 28:e525-e529. [PMID: 37330963 PMCID: PMC10635619 DOI: 10.4317/medoral.25919] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/18/2023] [Accepted: 05/08/2023] [Indexed: 06/20/2023] Open
Abstract
BACKGROUND Reactive cutaneous capillary endothelial proliferation (RCCEP), a special adverse event (AE) only observed in patients treated with camrelizumab, was reported to be correlated with the efficacy of camrelizumab in patients with advanced hepatocellular carcinoma. This study to analyze the possible correlation between the occurrence of RCCEP and efficacy of camrelizumab in patients with recurrent/metastatic head and neck squamous cell carcinoma (R/M HNSCC). MATERIAL AND METHODS In this study, we retrospectively analyzed the efficacy and RCCEP occurrence of camrelizumab in 58 patients with R/M HNSCC in the Shanghai Ninth People's Hospital affiliated to Shanghai JiaoTong University School of Medicine between January 2019 and June 2022. Kaplan-Meier analysis was used to assess the correlation between the occurrence of RCCEP and the survival of enrolled patients, and COX multifactor analysis was adopted to evaluate associated factors that affected the efficacy of camrelizumab immunotherapy. RESULTS A significant correlation between the incidence of RCCEP and a higher objective response rate was observed in this study (p=0.008). The occurrence of RCCEP was associated with better median overall survival (17.0 months vs. 8.7 months, p<0.0001, HR=5.944, 95% CI:2.097-16.84) and better median progression-free survival (15.1 months vs. 4.0 months, p<0.0001, HR=4.329,95% CI:1.683-11.13). In COX multifactor analysis, RCCEP occurrence was also an independent prognostic factor affecting OS and PFS in patients with R/M HNSCC. CONCLUSIONS The occurrence of RCCEP can show a better prognosis, it could be used as a clinical biomarker to predict the efficacy of camrelizumab treatment.
Collapse
Affiliation(s)
- Q Ding
- Department of Oral and Maxillofacial Surgery Ninth People's Hospital Shanghai Jiao Tong University School of Medicine Zip code: 200011, 639 Zhi-zao-ju Road, Shanghai, China
| | | | | | | | | | | | | | | |
Collapse
|
3
|
Seo A, Song H, Anakwenze CP, Ausat N, Chiao EY, Lin LL. Radiation Oncology Practice Changes during the COVID-19 Pandemic. Int J Radiat Oncol Biol Phys 2023; 117:e487. [PMID: 37785538 DOI: 10.1016/j.ijrobp.2023.06.1716] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/04/2023]
Abstract
PURPOSE/OBJECTIVE(S) The purpose of this study was to characterize the effects of institutional policies routine SARS-CoV-2 testing before treatment starts with mandatory quarantine periods for COVID-positive patients during the first year of the COVID19 pandemic across radiation oncology sections at our tertiary cancer center. MATERIALS/METHODS Electronic medical databases were queried to identify all patients treated with curative intent at a large urban cancer center and regional satellites a year prior to the pandemic (02/11/19-12/30/19; pre-pandemic) and the first year of the pandemic (03/11/20-12/30/20; post-pandemic). New treatment starts were filtered for those undergoing treatment under a single ICD-10 diagnosis and the first treatment in each time period for each patient. Chi-square tests were used for categorical variables, and the t-test was used for continuous variables to correlate differences in demographic and clinical factors before and during the pandemic. RESULTS The total number of new treatment starts were similar between the pre-pandemic (2,218 patients) and post-pandemic (2,130 patients) periods, but there was a 26% decrease in treatments in April 2020 compared to April 2019 and a 40% increase in treatments in November 2020 compared to November 2019. Post-pandemic patients had higher minimum Charlson Comorbidity Index scores (mean 46.0 vs 42.6, P = 0.0013) and were younger (62.8 yo vs 64.3 yo, P = 0.0001). The proportion of patients being treated from the same state as our institution was higher in the post-pandemic period compared to pre-pandemic (77.8% vs 72.43%, P = 0.0259). Distribution of treatments across department disease-site sections were significantly different (P<0.0001), with the proportion of patients treated by the Breast service having increased by 22% whereas the metropolitan area regional satellites experienced a 18% reduction. There were no statistically significant differences amongst pre- and post-pandemic patients with respect to race, marital status, or smoking status. Post-pandemic patients had less total radiation-related clinical visits (mean 24.8 vs 28.6, P<0.0001), lower administered dose (4329 cGy vs 4533 cGy, P<0.0001), and lower radiation fraction count (17 vs 19, P<0.0001). There was no statistically significant difference in the duration between CT simulation and treatment start, but post-pandemic patients had shorter duration of elapsed days during treatment (27 days vs 29 days, P = 0.0001). A disease-site-specific analysis demonstrated that these differences were most pronounced in patients treated for breast cancer. CONCLUSION In the first year of the COVID19 pandemic, our institution saw a dynamic change in the number of new radiation treatments. Additional analyses across individual disease-specific services may reveal insight into dose, fractionation, and technique, which may account for the observed differences.
Collapse
Affiliation(s)
- A Seo
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - H Song
- University of Texas MD Anderson Cancer Center, Houston, TX
| | - C P Anakwenze
- Division of Radiation Oncology, The University of Texas, MD Anderson Cancer Center, Houston, TX
| | - N Ausat
- The University of Texas MD Anderson Cancer Center, Houston, TX
| | - E Y Chiao
- Department of Epidemiology, The University of Texas MD Anderson Cancer Center, Houston, TX
| | - L L Lin
- Department of Radiation Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX
| |
Collapse
|
4
|
Kim M, Lee JL, Shin SJ, Bae WK, Lee HJ, Byun JH, Choi YJ, Youk J, Ock CY, Kim S, Song H, Park KH, Keam B. Phase II study of a trastuzumab biosimilar in combination with paclitaxel for HER2-positive recurrent or metastatic urothelial carcinoma: KCSG GU18-18. ESMO Open 2023; 8:101588. [PMID: 37385153 PMCID: PMC10485395 DOI: 10.1016/j.esmoop.2023.101588] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/09/2023] [Revised: 05/11/2023] [Accepted: 05/21/2023] [Indexed: 07/01/2023] Open
Abstract
BACKGROUND Human epidermal growth factor receptor 2 (HER2) is a widely explored therapeutic target in solid tumors. We evaluated the efficacy and safety of trastuzumab-pkrb, a biosimilar of trastuzumab, in combination with paclitaxel, in HER2-positive recurrent or metastatic urothelial carcinoma (UC). PATIENTS AND METHODS We enrolled 27 patients; they were administered a loading dose of 8 mg/kg trastuzumab-pkrb on day 1, followed by 6 mg/kg and 175 mg/m2 paclitaxel on day 1 every 3 weeks, intravenously. All patients received six cycles of the combination treatment and continued to receive trastuzumab-pkrb maintenance until disease progression, unacceptable toxicity, or for up to 2 years. HER2 positivity (based on immunohistochemistry analysis) was determined according to the 2013 American Society of Clinical Oncology /College of American Pathologists HER2 testing guidelines. The primary endpoint was objective response rate (ORR); the secondary endpoints were overall survival (OS), progression-free survival (PFS), and safety. RESULTS Twenty-six patients were evaluated via primary endpoint analysis. The ORR was 48.1% (1 complete and 12 partial responses) and the duration of response was 6.9 months [95% confidence interval (CI) 4.4-9.3 months]. With a median follow-up of 10.5 months, the median PFS and OS were 8.4 months (95% CI 6.2-8.8 months) and 13.5 months (95% CI 9.8 months-not reached), respectively. The most common treatment-related adverse event (TRAE) of any grade was peripheral neuropathy (88.9%). The most common grade 3/4 TRAEs were neutropenia (25.9%), thrombocytopenia (7.4%), and anemia (7.4%). CONCLUSIONS Trastuzumab-pkrb plus paclitaxel demonstrates promising efficacy with manageable toxicity profiles in patients with HER2-positive recurrent or metastatic UC.
Collapse
Affiliation(s)
- M Kim
- Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul; Cancer Research Institute, Seoul National University College of Medicine, Seoul
| | - J L Lee
- Department of Oncology and Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine, Seoul
| | - S J Shin
- Division of Oncology, Department of Internal Medicine, Yonsei University College of Medicine, Seoul
| | - W K Bae
- Department of Hemato-Oncology, Chonnam National University Medical School & Hwasun Hospital, Hwasun
| | - H J Lee
- Department of Internal Medicine, Chungnam National University College of Medicine, Daejeon
| | - J H Byun
- Department of Internal Medicine, Incheon St. Mary's Hospital, College of Medicine, The Catholic University of Korea, Incheon
| | - Y J Choi
- Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul
| | - J Youk
- Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul; Cancer Research Institute, Seoul National University College of Medicine, Seoul
| | - C Y Ock
- Lunit, Seoul, Republic of Korea
| | - S Kim
- Lunit, Seoul, Republic of Korea
| | - H Song
- Lunit, Seoul, Republic of Korea
| | - K H Park
- Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul
| | - B Keam
- Department of Internal Medicine, Seoul National University Hospital, Seoul National University College of Medicine, Seoul; Cancer Research Institute, Seoul National University College of Medicine, Seoul.
| |
Collapse
|
5
|
Zhang GZ, Zheng GQ, Wei F, Liu YY, Song H, Liang YF. [Pathological classification of malignant peritoneal mesothelioma and comparative analysis with peritoneal carcinomatosis]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 2023; 41:541-546. [PMID: 37524680 DOI: 10.3760/cma.j.cn121094-20211203-00597] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 08/02/2023]
Abstract
Objective: To analyze the pathological classification of malignant peritoneal mesothelioma (MPeM) and screen the immunohistochemical markers that can distinguish MPeM from peritoneal metastatic carcinoma (PC) . Methods: In June 2020, the pathological results of peritoneal biopsy of 158 MPeM and 138 PC patients from Cangzhou Central Hospital, Cangzhou People's Hospital, and Cangzhou Hospital of Integrated Traditional Chinese and Western Medicine from May 2011 to July 2019 were retrospectively analyzed, and the pathological classifications of MPeM in Cangzhou were summarized. Immunohistochemical markers of MPeM and PC patients were analyzed, and receiver operating characteristic curve (ROC curve) was drawn for differential diagnosis of MPeM and PC. Results: There were 55 male and 103 female MPeM patients in Cangzhou, with an average age of 57.1 years old. The asbestos exposure rate was 91.14% (144/158). The most common pathological classifications were cutaneous type, accounting for 90.51% (143/158). There were significant differences in the expression of calreticulum protein, CK5/6, vimentin, D2-40, carcinoembryonic antigen (CEA) and tail type homologous nuclear gene transcription factor 2 (CDX-2) between MPeM and PC (P<0.05). Among the 6 positive markers, the sensitivity of calreticulum protein was the highest (0.905) and CEA was the lowest (0.428) . Conclusion: Calreticulum protein, CK5/6, vimentin, D2-40, CEA and CDX-2 may be used as specific markers to distinguish the diagnosis of MPeM from PC.
Collapse
Affiliation(s)
- G Z Zhang
- Digestive Department, Cangzhou Central Hospital, Cangzhou 061001, China
| | - G Q Zheng
- Digestive Department, Cangzhou Central Hospital, Cangzhou 061001, China
| | - F Wei
- Digestive Department, Cangzhou Central Hospital, Cangzhou 061001, China
| | - Y Y Liu
- Digestive Department, Cangzhou Central Hospital, Cangzhou 061001, China
| | - H Song
- Digestive Department, Cangzhou Central Hospital, Cangzhou 061001, China
| | - Y F Liang
- Digestive Department, Cangzhou Central Hospital, Cangzhou 061001, China
| |
Collapse
|
6
|
Coverdale JPC, Kostrhunova H, Markova L, Song H, Postings M, Bridgewater HE, Brabec V, Rogers NJ, Scott P. Triplex metallohelices have enantiomer-dependent mechanisms of action in colon cancer cells. Dalton Trans 2023; 52:6656-6667. [PMID: 37114730 DOI: 10.1039/d3dt00948c] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/29/2023]
Abstract
Self-assembled enantiomers of an asymmetric di-iron metallohelix differ in their antiproliferative activities against HCT116 colon cancer cells such that the compound with Λ-helicity at the metals becomes more potent than the Δ compound with increasing exposure time. From concentration- and temperature-dependent 57Fe isotopic labelling studies of cellular accumulation we postulate that while the more potent Λ enantiomer undergoes carrier-mediated efflux, for Δ the process is principally equilibrative. Cell fractionation studies demonstrate that both enantiomers localise in a similar fashion; compound is observed mostly within the cytoskeleton and/or genomic DNA, with significant amounts also found in the nucleus and membrane, but with negligible concentration in the cytosol. Cell cycle analyses using flow cytometry reveal that the Δ enantiomer induces mild arrest in the G1 phase, while Λ causes a very large dose-dependent increase in the G2/M population at a concentration significantly below the relevant IC50. Correspondingly, G2-M checkpoint failure as a result of Λ-metallohelix binding to DNA is shown to be feasible by linear dichroism studies, which indicate, in contrast to the Δ compound, a quite specific mode of binding, probably in the major groove. Further, spindle assembly checkpoint (SAC) failure, which could also be responsible for the observed G2/M arrest, is established as a feasible mechanism for the Λ helix via drug combination (synergy) studies and the discovery of tubulin and actin inhibition. Here, while the Λ compound stabilizes F-actin and induces a distinct change in tubulin architecture of HCT116 cells, Δ promotes depolymerization and more subtle changes in microtubule and actin networks.
Collapse
Affiliation(s)
- J P C Coverdale
- Department of Chemistry, University of Warwick, Coventry, CV4 7AL, UK
- School of Pharmacy, Institute of Clinical Sciences, University of Birmingham, Edgbaston, B15 2TT, UK
| | - H Kostrhunova
- The Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, CZ-61265 Brno, Czech Republic
| | - L Markova
- The Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, CZ-61265 Brno, Czech Republic
| | - H Song
- Department of Chemistry, University of Warwick, Coventry, CV4 7AL, UK
- Beijing Area Major Laboratory of Peptide and Small Molecular Drugs, School of Pharmaceutical Sciences, Capital Medical University, Beijing, 100069, China
| | - M Postings
- Department of Chemistry, University of Warwick, Coventry, CV4 7AL, UK
| | - H E Bridgewater
- Department of Chemistry, University of Warwick, Coventry, CV4 7AL, UK
- Centre of Exercise, Sport and Life Science, Faculty of Health and Life Sciences, Coventry University, Coventry, CV1 5FB, UK
| | - V Brabec
- The Czech Academy of Sciences, Institute of Biophysics, Kralovopolska 135, CZ-61265 Brno, Czech Republic
| | - N J Rogers
- Department of Chemistry, University of Warwick, Coventry, CV4 7AL, UK
| | - P Scott
- Department of Chemistry, University of Warwick, Coventry, CV4 7AL, UK
| |
Collapse
|
7
|
Abe S, Asami S, Eizuka M, Futagi S, Gando A, Gando Y, Gima T, Goto A, Hachiya T, Hata K, Hayashida S, Hosokawa K, Ichimura K, Ieki S, Ikeda H, Inoue K, Ishidoshiro K, Kamei Y, Kawada N, Kishimoto Y, Koga M, Kurasawa M, Maemura N, Mitsui T, Miyake H, Nakahata T, Nakamura K, Nakamura K, Nakamura R, Ozaki H, Sakai T, Sambonsugi H, Shimizu I, Shirai J, Shiraishi K, Suzuki A, Suzuki Y, Takeuchi A, Tamae K, Ueshima K, Watanabe H, Yoshida Y, Obara S, Ichikawa AK, Chernyak D, Kozlov A, Nakamura KZ, Yoshida S, Takemoto Y, Umehara S, Fushimi K, Kotera K, Urano Y, Berger BE, Fujikawa BK, Learned JG, Maricic J, Axani SN, Smolsky J, Fu Z, Winslow LA, Efremenko Y, Karwowski HJ, Markoff DM, Tornow W, Dell'Oro S, O'Donnell T, Detwiler JA, Enomoto S, Decowski MP, Grant C, Li A, Song H. Search for the Majorana Nature of Neutrinos in the Inverted Mass Ordering Region with KamLAND-Zen. Phys Rev Lett 2023; 130:051801. [PMID: 36800472 DOI: 10.1103/physrevlett.130.051801] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/04/2022] [Revised: 04/10/2022] [Accepted: 11/29/2022] [Indexed: 06/18/2023]
Abstract
The KamLAND-Zen experiment has provided stringent constraints on the neutrinoless double-beta (0νββ) decay half-life in ^{136}Xe using a xenon-loaded liquid scintillator. We report an improved search using an upgraded detector with almost double the amount of xenon and an ultralow radioactivity container, corresponding to an exposure of 970 kg yr of ^{136}Xe. These new data provide valuable insight into backgrounds, especially from cosmic muon spallation of xenon, and have required the use of novel background rejection techniques. We obtain a lower limit for the 0νββ decay half-life of T_{1/2}^{0ν}>2.3×10^{26} yr at 90% C.L., corresponding to upper limits on the effective Majorana neutrino mass of 36-156 meV using commonly adopted nuclear matrix element calculations.
Collapse
Affiliation(s)
- S Abe
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - S Asami
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - M Eizuka
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - S Futagi
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - A Gando
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - Y Gando
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - T Gima
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - A Goto
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - T Hachiya
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - K Hata
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - S Hayashida
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - K Hosokawa
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - K Ichimura
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - S Ieki
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - H Ikeda
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - K Inoue
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, The University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - K Ishidoshiro
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - Y Kamei
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - N Kawada
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - Y Kishimoto
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, The University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - M Koga
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, The University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - M Kurasawa
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - N Maemura
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - T Mitsui
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - H Miyake
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - T Nakahata
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - K Nakamura
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - K Nakamura
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - R Nakamura
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - H Ozaki
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
- Graduate Program on Physics for the Universe, Tohoku University, Sendai 980-8578, Japan
| | - T Sakai
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - H Sambonsugi
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - I Shimizu
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - J Shirai
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - K Shiraishi
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - A Suzuki
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - Y Suzuki
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - A Takeuchi
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - K Tamae
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - K Ueshima
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - H Watanabe
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - Y Yoshida
- Research Center for Neutrino Science, Tohoku University, Sendai 980-8578, Japan
| | - S Obara
- Frontier Research Institute for Interdisciplinary Sciences, Tohoku University, Sendai 980-8578, Japan
| | - A K Ichikawa
- Department of Physics, Tohoku University, Sendai 980-8578, Japan
| | - D Chernyak
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, The University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - A Kozlov
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, The University of Tokyo, Kashiwa, Chiba 277-8583, Japan
| | - K Z Nakamura
- Kyoto University, Department of Physics, Kyoto 606-8502, Japan
| | - S Yoshida
- Graduate School of Science, Osaka University, Toyonaka, Osaka 560-0043, Japan
| | - Y Takemoto
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - S Umehara
- Research Center for Nuclear Physics, Osaka University, Ibaraki, Osaka 567-0047, Japan
| | - K Fushimi
- Department of Physics, Tokushima University, Tokushima 770-8506, Japan
| | - K Kotera
- Graduate School of Integrated Arts and Sciences, Tokushima University, Tokushima 770-8502, Japan
| | - Y Urano
- Graduate School of Integrated Arts and Sciences, Tokushima University, Tokushima 770-8502, Japan
| | - B E Berger
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, The University of Tokyo, Kashiwa, Chiba 277-8583, Japan
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - B K Fujikawa
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, The University of Tokyo, Kashiwa, Chiba 277-8583, Japan
- Nuclear Science Division, Lawrence Berkeley National Laboratory, Berkeley, California 94720, USA
| | - J G Learned
- Department of Physics and Astronomy, University of Hawaii at Manoa, Honolulu, Hawaii 96822, USA
| | - J Maricic
- Department of Physics and Astronomy, University of Hawaii at Manoa, Honolulu, Hawaii 96822, USA
| | - S N Axani
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - J Smolsky
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - Z Fu
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - L A Winslow
- Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - Y Efremenko
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, The University of Tokyo, Kashiwa, Chiba 277-8583, Japan
- Department of Physics and Astronomy, University of Tennessee, Knoxville, Tennessee 37996, USA
| | - H J Karwowski
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA; Physics Departments at Duke University, Durham, North Carolina 27708, USA; North Carolina Central University, Durham, North Carolina 27707, USA; and The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
| | - D M Markoff
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA; Physics Departments at Duke University, Durham, North Carolina 27708, USA; North Carolina Central University, Durham, North Carolina 27707, USA; and The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
| | - W Tornow
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, The University of Tokyo, Kashiwa, Chiba 277-8583, Japan
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA; Physics Departments at Duke University, Durham, North Carolina 27708, USA; North Carolina Central University, Durham, North Carolina 27707, USA; and The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
| | - S Dell'Oro
- Center for Neutrino Physics, Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061, USA
| | - T O'Donnell
- Center for Neutrino Physics, Virginia Polytechnic Institute and State University, Blacksburg, Virginia 24061, USA
| | - J A Detwiler
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, The University of Tokyo, Kashiwa, Chiba 277-8583, Japan
- Center for Experimental Nuclear Physics and Astrophysics, University of Washington, Seattle, Washington 98195, USA
| | - S Enomoto
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, The University of Tokyo, Kashiwa, Chiba 277-8583, Japan
- Center for Experimental Nuclear Physics and Astrophysics, University of Washington, Seattle, Washington 98195, USA
| | - M P Decowski
- Kavli Institute for the Physics and Mathematics of the Universe (WPI), The University of Tokyo Institutes for Advanced Study, The University of Tokyo, Kashiwa, Chiba 277-8583, Japan
- Nikhef and the University of Amsterdam, Science Park, Amsterdam, Netherlands
| | - C Grant
- Boston University, Boston, Massachusetts 02215, USA
| | - A Li
- Triangle Universities Nuclear Laboratory, Durham, North Carolina 27708, USA; Physics Departments at Duke University, Durham, North Carolina 27708, USA; North Carolina Central University, Durham, North Carolina 27707, USA; and The University of North Carolina at Chapel Hill, Chapel Hill, North Carolina 27599, USA
- Boston University, Boston, Massachusetts 02215, USA
| | - H Song
- Boston University, Boston, Massachusetts 02215, USA
| |
Collapse
|
8
|
Nedbailo R, Park J, Hollinger R, Wang S, Mariscal D, Morrison J, Song H, Zeraouli G, Scott GG, Ma T, Rocca JJ. Compact high repetition rate Thomson parabola ion spectrometer. Rev Sci Instrum 2023; 94:023505. [PMID: 36859067 DOI: 10.1063/5.0101859] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/03/2022] [Accepted: 01/04/2023] [Indexed: 06/18/2023]
Abstract
We present the development of a compact Thomson parabola ion spectrometer capable of characterizing the energy spectra of various ion species of multi-MeV ion beams from >1020W/cm2 laser produced plasmas at rates commensurate with the highest available from any of the current and near-future PW-class laser facilities. This diagnostic makes use of a polyvinyl toluene based fast plastic scintillator (EJ-260), and the emitted light is collected using an optical imaging system coupled to a thermoelectrically cooled scientific complementary metal-oxide-semiconductor camera. This offers a robust solution for data acquisition at a high repetition rate, while avoiding the added complications and nonlinearities of micro-channel plate based systems. Different ion energy ranges can be probed using a modular magnet setup, a variable electric field, and a varying drift-distance. We have demonstrated operation and data collection with this system at up to 0.2 Hz from plasmas created by irradiating a solid target, limited only by the targeting system. With the appropriate software, on-the-fly ion spectral analysis will be possible, enabling real-time experimental control at multi-Hz repetition rates.
Collapse
Affiliation(s)
- R Nedbailo
- Electrical and Computer Engineering Department, Colorado State University, Fort Collins, Colorado 80523, USA
| | - J Park
- Electrical and Computer Engineering Department, Colorado State University, Fort Collins, Colorado 80523, USA
| | - R Hollinger
- Electrical and Computer Engineering Department, Colorado State University, Fort Collins, Colorado 80523, USA
| | - S Wang
- Electrical and Computer Engineering Department, Colorado State University, Fort Collins, Colorado 80523, USA
| | - D Mariscal
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - J Morrison
- Electrical and Computer Engineering Department, Colorado State University, Fort Collins, Colorado 80523, USA
| | - H Song
- Electrical and Computer Engineering Department, Colorado State University, Fort Collins, Colorado 80523, USA
| | - G Zeraouli
- Electrical and Computer Engineering Department, Colorado State University, Fort Collins, Colorado 80523, USA
| | - G G Scott
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - T Ma
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - J J Rocca
- Electrical and Computer Engineering Department, Colorado State University, Fort Collins, Colorado 80523, USA
| |
Collapse
|
9
|
Rai PK, Sonne C, Song H, Kim KH. Plastic wastes in the time of COVID-19: Their environmental hazards and implications for sustainable energy resilience and circular bio-economies. Sci Total Environ 2023; 858:159880. [PMID: 36328266 PMCID: PMC9618453 DOI: 10.1016/j.scitotenv.2022.159880] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/02/2022] [Revised: 10/28/2022] [Accepted: 10/28/2022] [Indexed: 06/06/2023]
Abstract
The global scope of pollution from plastic waste is a well-known phenomenon associated with trade, mass consumption, and disposal of plastic products (e.g., personal protective equipment (PPE), viral test kits, and vacuum-packaged food). Recently, the scale of the problem has been exacerbated by increases in indoor livelihood activities during lockdowns imposed in response to the coronavirus disease 2019 (COVID-19) pandemic. The present study describes the effects of increased plastic waste on environmental footprint and human health. Further, the technological/regulatory options and life cycle assessment (LCA) approach for sustainable plastic waste management are critically dealt in terms of their implications on energy resilience and circular economy. The abrupt increase in health-care waste during pandemic has been worsening environmental quality to undermine the sustainability in general. In addition, weathered plastic particles from PPE along with microplastics (MPs) and nanoplastics (NPs) can all adsorb chemical and microbial contaminants to pose a risk to ecosystems, biota, occupational safety, and human health. PPE-derived plastic pollution during the pandemic also jeopardizes sustainable development goals, energy resilience, and climate control measures. However, it is revealed that the pandemic can be regarded as an opportunity for explicit LCA to better address the problems associated with environmental footprints of plastic waste and to focus on sustainable management technologies such as circular bio-economies, biorefineries, and thermal gasification. Future researches in the energy-efficient clean technologies and circular bio-economies (or biorefineries) in concert with a "nexus" framework are expected to help reduce plastic waste into desirable directions.
Collapse
Affiliation(s)
- Prabhat Kumar Rai
- Phyto-Technologies and Plant Invasion Lab, Department of Environmental Science, School of Earth Sciences and Natural Resources Management, Mizoram University, Aizawl, Mizoram, India
| | - C Sonne
- Department of Ecoscience, Arctic Research Centre, Aarhus University, Frederiksborgvej 399, DK-4000 Roskilde, Denmark
| | - H Song
- Department of Earth Resources and Environmental Engineering, Hanyang University, 222 Wangsimni-Ro, Seoul 04763, Republic of Korea
| | - Ki-Hyun Kim
- Department of Civil & Environmental Engineering, Hanyang University, 222 Wangsimni-Ro, Seoul 04763, Republic of Korea.
| |
Collapse
|
10
|
Mariscal DA, Djordjević BZ, Anirudh R, Bremer T, Campbell PC, Feister S, Folsom E, Grace ES, Hollinger R, Jacobs SA, Kailkhura B, Kalantar D, Kemp AJ, Kim J, Kur E, Liu S, Ludwig J, Morrison J, Nedbailo R, Ose N, Park J, Rocca JJ, Scott GG, Simpson RA, Song H, Spears B, Sullivan B, Swanson KK, Thiagarajan J, Wang S, Williams GJ, Wilks SC, Wyatt M, Van Essen B, Zacharias R, Zeraouli G, Zhang J, Ma T. A flexible proton beam imaging energy spectrometer (PROBIES) for high repetition rate or single-shot high energy density (HED) experiments (invited). Rev Sci Instrum 2023; 94:023507. [PMID: 36859040 DOI: 10.1063/5.0101845] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/03/2022] [Accepted: 12/28/2022] [Indexed: 06/18/2023]
Abstract
The PROBIES diagnostic is a new, highly flexible, imaging and energy spectrometer designed for laser-accelerated protons. The diagnostic can detect low-mode spatial variations in the proton beam profile while resolving multiple energies on a single detector or more. When a radiochromic film stack is employed for "single-shot mode," the energy resolution of the stack can be greatly increased while reducing the need for large numbers of films; for example, a recently deployed version allowed for 180 unique energy measurements spanning ∼3 to 75 MeV with <0.4 MeV resolution using just 20 films vs 180 for a comparable traditional film and filter stack. When utilized with a scintillator, the diagnostic can be run in high-rep-rate (>Hz rate) mode to recover nine proton energy bins. We also demonstrate a deep learning-based method to analyze data from synthetic PROBIES images with greater than 95% accuracy on sub-millisecond timescales and retrained with experimental data to analyze real-world images on sub-millisecond time-scales with comparable accuracy.
Collapse
Affiliation(s)
- D A Mariscal
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - B Z Djordjević
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - R Anirudh
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - T Bremer
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - P C Campbell
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - S Feister
- Department of Computer Science, California State University Channel Islands, Camarillo, California 93012, USA
| | - E Folsom
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - E S Grace
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - R Hollinger
- Colorado State University, Fort Collins, Colorado 80523, USA
| | - S A Jacobs
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - B Kailkhura
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - D Kalantar
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - A J Kemp
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - J Kim
- Center for Energy Research, University of California San Diego, La Jolla, California 92093, USA
| | - E Kur
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - S Liu
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - J Ludwig
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - J Morrison
- Colorado State University, Fort Collins, Colorado 80523, USA
| | - R Nedbailo
- Colorado State University, Fort Collins, Colorado 80523, USA
| | - N Ose
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - J Park
- Colorado State University, Fort Collins, Colorado 80523, USA
| | - J J Rocca
- Colorado State University, Fort Collins, Colorado 80523, USA
| | - G G Scott
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - R A Simpson
- Department of Nuclear Science and Engineering, Massachusetts Institute of Technology, Cambridge, Massachusetts 02139, USA
| | - H Song
- Colorado State University, Fort Collins, Colorado 80523, USA
| | - B Spears
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - B Sullivan
- Colorado State University, Fort Collins, Colorado 80523, USA
| | - K K Swanson
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - J Thiagarajan
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - S Wang
- Colorado State University, Fort Collins, Colorado 80523, USA
| | - G J Williams
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - S C Wilks
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - M Wyatt
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - B Van Essen
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - R Zacharias
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - G Zeraouli
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - J Zhang
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - T Ma
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| |
Collapse
|
11
|
Bang HJ, Jeong WJ, Cha K, Oh SH, Park KN, Youn CS, Kim HJ, Lim JY, Kim HJ, Song H. A novel cardiac arrest severity score for the early prediction of hypoxic-ischemic brain injury and in-hospital death. Eur Heart J 2023. [DOI: 10.1093/eurheartj/ehac779.065] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Background
Out-of-hospital cardiac arrest (OHCA) outcomes are unsatisfactory despite postcardiac arrest care. Early prediction of prognoses might help stratify patients and provide tailored therapy.
Purpose
In this study, we derived and validated a novel scoring system to predict hypoxic-ischaemic brain injury (HIBI) and in-hospital death (IHD).
Methods
We retrospectively analysed Korean Hypothermia Network prospective registry data collected from in Korea between 2015 and 2018. Patients without neuroprognostication data were excluded, and the remaining patients were randomly divided into derivation and validation cohorts. HIBI was defined when at least one prognostication predicted a poor outcome. IHD meant all deaths regardless of cause. In the derivation cohort, stepwise multivariate logistic regression was conducted for HIBI and IHD scores, and model performance was assessed. We then classified patients into four categories and analysed associations between the categories and cerebral performance categories (CPCs) at hospital discharge. Finally, we validated our models in the internal validation cohort.
Results
Among 1373 patients, 240 were excluded, and 1133 were randomised into derivation (n=754) and validation cohorts (n=379). In the derivation cohort, 7 and 8 predictors were selected for HIBI (0–8) and IHD scores (0–11), respectively, and the area under the curve (AUC) was 0.85 (95% CI 0.82–0.87) and 0.80 (95% CI 0.77–0.82), respectively. Applying optimum cutoff values of ≥6 points for HIBI and ≥7 points for IHD, patients were classified as follows: HIBI (-)/IHD (-), Category 1 (n=424); HIBI (-)/IHD (+), Category 2 (n=100); HIBI (+)/IHD (-), Category 3 (n=21); and HIBI (+)/IHD (+), Category 4 (n=209). CPCs at discharge were significantly different in each category (p<0.001). In the validation cohort, the model showed moderate discrimination (AUC 0.83, 95% CI 0.79–0.87 for HIBI and AUC 0.77, 95% CI 0.72–0.81 for IHD) with good calibration. Each category of the validation cohort showed a significant difference in discharge outcomes (p<0.001) and a similar trend to the derivation cohort.
Conclusions
We presented a novel approach for assessing illness severity after OHCA. Although external prospective studies are warranted, risk stratification for HIBI and IHD could help provide OHCA patients with appropriate treatment.
Collapse
Affiliation(s)
- H J Bang
- The Catholic University of Korea Seoul St. Mary's Hospital, Emergency medicine , Seoul , Korea (Republic of)
| | - W J Jeong
- St. Vincent's Hospital, Emergency medicine , Suwon , Korea (Democratic People's Republic of)
| | - K Cha
- St. Vincent's Hospital, Emergency medicine , Suwon , Korea (Democratic People's Republic of)
| | - S H Oh
- The Catholic University of Korea Seoul St. Mary's Hospital, Emergency medicine , Seoul , Korea (Republic of)
| | - K N Park
- The Catholic University of Korea Seoul St. Mary's Hospital, Emergency medicine , Seoul , Korea (Republic of)
| | - C S Youn
- The Catholic University of Korea Seoul St. Mary's Hospital, Emergency medicine , Seoul , Korea (Republic of)
| | - H J Kim
- The Catholic University of Korea Seoul St. Mary's Hospital, Emergency medicine , Seoul , Korea (Republic of)
| | - J Y Lim
- The Catholic University of Korea Seoul St. Mary's Hospital, Emergency medicine , Seoul , Korea (Republic of)
| | - H J Kim
- The Catholic University of Korea Seoul St. Mary's Hospital, Emergency medicine , Seoul , Korea (Republic of)
| | - H Song
- St. Vincent's Hospital, Emergency medicine , Suwon , Korea (Democratic People's Republic of)
| |
Collapse
|
12
|
Song H. Novel serum biomarkers for predicting prognosis in post cardiac arrest patients. Eur Heart J 2023. [DOI: 10.1093/eurheartj/ehac779.066] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 01/26/2023] Open
Abstract
Abstract
Funding Acknowledgements
Type of funding sources: None.
Objective
To determine the clinical feasibility of novel serum biomarkers by comparing them with conventional serum biomarkers in out-of-hospital cardiac arrest (OHCA) patients treated with target temperature management (TTM).
Methods
This study was a prospective observational study conducted on OHCA patients who underwent TTM. We measured serum biomarker Neuron‑Specific Enolase (NSE), S-100B (S100 calcium-binding protein), Tau protein, Glial Fibrillary Acidic Protein (GFAP), Neurofilament Light Chain (NFL), and Ubiquitin C-terminal hydrolase-L1 (UCH-L1) at 0, 24, 48, and 72 hours after return of spontaneous circulation (ROSC). Conventional biomarkers include NSE and S-100B. The primary outcome was good neurologic outcome at 6 months after OHCA.
Results
A total of 100 patients were included in this study from August 2018 to May 2020. Among the included patients, 46 patients had good neurologic outcomes. As for the biomarker's AUC value measured immediately after ROSC, GFAP had the highest value (0.850), and among the values measured 24 hours after ROSC, S100B showed the highest value (0.901). The AUC values of biomarkers measured after 48 hours and 72 hours after ROSC, were the highest in NFL (0.921, 0.946). AUC values measured after 72 hours of ROSC showed higher values in novel biomarkers than in conventional biomarkers.
Conclusion
After 72 hours of ROSC, the Novel biomarkers showed a higher AUC value than the conventional biomarkers. Among them, NFL showed the highest AUC values than other biomarkers at 48 and 72 hours of ROSC.
Collapse
Affiliation(s)
- H Song
- St. Vincent Hospital , Suwon , Korea (Republic of)
| |
Collapse
|
13
|
Xu H, Zheng H, Zhang Q, Song H, Wang Q, Xiao J, Dong Y, Shen Z, Wang S, Wu S, Wei Y, Lu W, Zhu Y, Niu X. A Multicentre Clinical Study of Sarcoma Personalised Treatment Using Patient-Derived Tumour Xenografts. Clin Oncol (R Coll Radiol) 2023; 35:e48-e59. [PMID: 35781406 DOI: 10.1016/j.clon.2022.06.002] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/08/2021] [Revised: 04/21/2022] [Accepted: 06/09/2022] [Indexed: 01/04/2023]
Abstract
AIMS Medication for advanced sarcomas has not improved for three decades. Patient-derived tumour xenografts (PDTX) are a promising solution for developing new therapies and real-time personalised medicine because of their highly effective prediction of drug efficacy. However, there is a dearth of PDTX models for sarcomas due to the scarcity and heterogeneity of the disease. MATERIALS AND METHODS A multicentre clinical collaborative study (ChiCTR-OOC-17013617) was carried out. Fresh patient tumour tissues via resection or biopsy were used for the PDTX set-up. The standard medical care chosen by the physician was given to the patient, in parallel with testing on multiple regimens. The outcomes of patients' responses and PDTX tests were compared. Comprehensive analyses were carried out to assess the clinical value of PDTX for the treatment of sarcomas. Living tissues from successfully engrafted cases were deposited into a repository. RESULTS Forty-two cases, including 36 bone sarcomas and six soft-tissue sarcomas, were enrolled; the overall engraftment rate was 73.8%. Histopathological examination showed a 100% consistency between primary tumours and tumour grafts. The engraftment rate was independent of age, gender and sampling methods, but was associated with subtypes of tumour. The outgrowth time of tumour grafts could be associated with prognosis. Major somatic mutations in tumour grafts occurred primarily in common tumour driver genes. Poor prognosis was associated with the KMT2C mutation. A drug efficacy test showed complete concordance between the PDTX model and patients' responses in 17 regimens. CONCLUSION PDTX is an ideal preclinical model for sarcomas because of its faithful preservation of the heterogeneity of the disease, a satisfactory engraftment rate and high accuracy in its prediction of drug efficacy.
Collapse
Affiliation(s)
- H Xu
- Beijing Jishuitan Hospital, Beijing, China
| | - H Zheng
- Nanjing Personal Oncology Biological Technology Co. Ltd, Nanjing, China
| | - Q Zhang
- Beijing Jishuitan Hospital, Beijing, China
| | - H Song
- Nanjing Personal Oncology Biological Technology Co. Ltd, Nanjing, China
| | - Q Wang
- Nanjing Personal Oncology Biological Technology Co. Ltd, Nanjing, China
| | - J Xiao
- Changzheng Hospital, Shanghai, China
| | - Y Dong
- The Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, China
| | - Z Shen
- The Sixth People's Hospital, Shanghai Jiao Tong University, Shanghai, China
| | - S Wang
- Spine Surgery, Drum Tower Hospital, Nanjing University Medical School, Nanjing, China
| | - S Wu
- Jinling Hospital, Nanjing, Jiangsu, China
| | - Y Wei
- The First Affiliated Hospital of Nanjing Medical University, Nanjing, China
| | - W Lu
- Zhongshan Hospital, Fudan University, Shanghai, China
| | - Y Zhu
- Nanjing Personal Oncology Biological Technology Co. Ltd, Nanjing, China
| | - X Niu
- Beijing Jishuitan Hospital, Beijing, China.
| |
Collapse
|
14
|
Baek Y, Kwak E, Kim Y, Kim A, Song H, Jeon J. 088 Periodontal disease does not increase the risk of subsequent psoriasis: a nationwide population-based cohort study in Korea. J Invest Dermatol 2022. [DOI: 10.1016/j.jid.2022.09.098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
15
|
Zeraouli G, Mariscal D, Grace E, Scott GG, Swanson KK, Simpson R, Djordjevic BZ, Nedbailo R, Song H, Morrison J, Park J, Hollinger R, Wang S, Rocca JJ, Ma T. Ultra-compact x-ray spectrometer for high-repetition-rate laser-plasma experiments. Rev Sci Instrum 2022; 93:113508. [PMID: 36461516 DOI: 10.1063/5.0100970] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 05/27/2022] [Accepted: 09/28/2022] [Indexed: 06/17/2023]
Abstract
We present in this work the development of an ultra-compact, multi-channel x-ray spectrometer (UCXS). This diagnostic has been specially built and adapted to perform at high-repetition-rate (>1 Hz) for high-intensity, short-pulse laser plasma experiments. X-ray filters of varying materials and thicknesses are chosen to provide spectral resolution up to ΔE ≈ 1 keV over the x-ray energy range of 1-30 keV. These filters are distributed over a total of 25 channels, where each x-ray filter is coupled to a single scintillator. The UCXS is designed to detect and resolve a large variety of laser-driven x-ray sources such as low energy bremsstrahlung emission, fluorescence, and betatron radiation (up to 30 keV). Preliminary results from commissioning experiments at the ABL laser facility at Colorado State University are provided.
Collapse
Affiliation(s)
- G Zeraouli
- Colorado State University, Fort Collins, Colorado 80523, USA
| | - D Mariscal
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - E Grace
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - G G Scott
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - K K Swanson
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - R Simpson
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - B Z Djordjevic
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - R Nedbailo
- Colorado State University, Fort Collins, Colorado 80523, USA
| | - H Song
- Colorado State University, Fort Collins, Colorado 80523, USA
| | - J Morrison
- Colorado State University, Fort Collins, Colorado 80523, USA
| | - J Park
- Colorado State University, Fort Collins, Colorado 80523, USA
| | - R Hollinger
- Colorado State University, Fort Collins, Colorado 80523, USA
| | - S Wang
- Colorado State University, Fort Collins, Colorado 80523, USA
| | - J J Rocca
- Colorado State University, Fort Collins, Colorado 80523, USA
| | - T Ma
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| |
Collapse
|
16
|
Altibi A, Ghanem F, Patel J, Al-Taweel O, Chadderdon S, Song H, Lantz G, Zahr F, Golwala H. Hospital procedural volume and clinical outcomes for transcatheter aortic valve replacement – US nationwide readmission database, 2016–2019. Eur Heart J 2022. [DOI: 10.1093/eurheartj/ehac544.2097] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
Abstract
Abstract
Background
The number of hospitals offering transcatheter aortic valve replacement (TAVR) programs has increased exponentially in the United States over past several years. Multiple prior studies indicate relationship between hospital volume and clinical outcomes for various cardiac procedures.
Purpose
The association between the hospital procedural volume and clinical outcomes for TAVR is yet poorly understood. In this study, we aim to examine the in-hospital outcomes after TAVR stratified by hospital volume within a nationally representative, large database.
Methods
The National Readmission Database (NRD) 2016–2019 was used to identify hospitals with established TAVR programs (performing ≥20 TAVRs/year). Based on annualized procedural volume of transfemoral TAVR, hospitals were stratified into tertiles of low, medium, and high volume TAVR centers. Rates of adverse in-hospital events (death, cardiac arrest, stroke, vascular complications, and permanent pacemaker), 30-day mortality, and 30-day readmission rates were examined. Multivariate logistic regression analysis was performed to compare overall outcomes following TAVR in low-, medium-, and high-volume centers; adjusted for baseline characteristics and comorbidity burden.
Results
Of 71 million discharge records reviewed, a total of 232,581 patients underwent transfemoral TAVR between 2016–2019. Of all the TAVR cases, 77,183 (33.2%), 75,987 (32.7%), and 79,411 (34.1%) were performed at low-, medium-, and high-volume hospitals respectively. The median number of annual TAVR procedures was 91, 229, and 456 in low-, medium-, and high-volume centers respectively. Adjusted in-hospital mortality was significantly higher in low-volume (OR: 1.40, 95% CI: 1.21–1.62, p<0.01) and medium-volume (OR: 1.29, 95% CI: 1.11–1.50, p<0.01) hospitals compared with high-volume centers. Similarly, adjusted 30-day mortality (OR: 1.45, 95% CI: 1.27–1.66, p<0.01), 30-day readmission rates (OR: 1.11, 95% CI: 1.05–1.18, p<0.01), and in-hospital cardiac arrest (OR: 1.20, 95% CI: 1.08–1.33, p<0.01) were significantly higher for centers in the lowest-volume tertile compared with those in the highest-volume tertile. There were no significant differences in hospital length of stay (mean, 4.3±6.5 days), in-hospital stroke, acute kidney injury, vascular complications, need for permanent pacemaker, or mechanical circulatory support post-TAVR between the three groups.
Conclusion
In the United States, an inverse volume-mortality relationship was observed for transfemoral TAVR procedures from 2016 through 2019. Mortality and readmission rates at 30 days post-TAVR were significantly higher at low-volume hospitals compared with high-volume hospitals. Further research focusing at establishing protocols and standardized training programs may help mitigate the discrepancy in TAVR outcomes amongst hospitals with discrepant procedural volume.
Funding Acknowledgement
Type of funding sources: None.
Collapse
Affiliation(s)
- A Altibi
- Oregon Health & Science University , Portland , United States of America
| | - F Ghanem
- East Tennessee State University, Cardiovascular Medicine , Johnson , United States of America
| | - J Patel
- East Tennessee State University, Cardiovascular Medicine , Johnson , United States of America
| | - O Al-Taweel
- University of Nevada, Las Vegas School of Medicine, Cardiovascular Medicine , Las Vegas , United States of America
| | - S Chadderdon
- Oregon Health & Science University , Portland , United States of America
| | - H Song
- Oregon Health & Science University , Portland , United States of America
| | - G Lantz
- Oregon Health & Science University , Portland , United States of America
| | - F Zahr
- Oregon Health & Science University , Portland , United States of America
| | - H Golwala
- Oregon Health & Science University , Portland , United States of America
| |
Collapse
|
17
|
Swanson KK, Mariscal DA, Djordjevic BZ, Zeraouli G, Scott GG, Hollinger R, Wang S, Song H, Sullivan B, Nedbailo R, Rocca JJ, Ma T. Applications of machine learning to a compact magnetic spectrometer for high repetition rate, laser-driven particle acceleration. Rev Sci Instrum 2022; 93:103547. [PMID: 36319355 DOI: 10.1063/5.0101857] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/03/2022] [Accepted: 09/20/2022] [Indexed: 06/16/2023]
Abstract
Accurately and rapidly diagnosing laser-plasma interactions is often difficult due to the time-intensive nature of the analysis and will only become more so with the rise of high repetition rate lasers and the desire to implement feedback on a commensurate timescale. Diagnostic analysis employing machine learning techniques can help address this problem while maintaining a high degree of accuracy. We report on the application of machine learning to the analysis of a scintillator-based electron spectrometer for experiments on high intensity, laser-plasma interactions at the Colorado State University Advanced Lasers and Extreme Photonics facility. Our approach utilizes a neural network trained on synthetic data and tested on experiments to extract the accelerated electron temperature. By leveraging transfer learning, we demonstrate an improvement in the neural network accuracy, decreasing the network error by 50%.
Collapse
Affiliation(s)
- K K Swanson
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - D A Mariscal
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - B Z Djordjevic
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - G Zeraouli
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - G G Scott
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - R Hollinger
- Colorado State University, Fort Collins, Colorado 80523, USA
| | - S Wang
- Colorado State University, Fort Collins, Colorado 80523, USA
| | - H Song
- Colorado State University, Fort Collins, Colorado 80523, USA
| | - B Sullivan
- Colorado State University, Fort Collins, Colorado 80523, USA
| | - R Nedbailo
- Colorado State University, Fort Collins, Colorado 80523, USA
| | - J J Rocca
- Colorado State University, Fort Collins, Colorado 80523, USA
| | - T Ma
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| |
Collapse
|
18
|
Beier NF, Allison H, Efthimion P, Flippo KA, Gao L, Hansen SB, Hill K, Hollinger R, Logantha M, Musthafa Y, Nedbailo R, Senthilkumaran V, Shepherd R, Shlyaptsev VN, Song H, Wang S, Dollar F, Rocca JJ, Hussein AE. Homogeneous, Micron-Scale High-Energy-Density Matter Generated by Relativistic Laser-Solid Interactions. Phys Rev Lett 2022; 129:135001. [PMID: 36206410 DOI: 10.1103/physrevlett.129.135001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/02/2022] [Revised: 08/01/2022] [Accepted: 08/26/2022] [Indexed: 06/16/2023]
Abstract
Short-pulse, laser-solid interactions provide a unique platform for studying complex high-energy-density matter. We present the first demonstration of solid-density, micron-scale keV plasmas uniformly heated by a high-contrast, 400 nm wavelength laser at intensities up to 2×10^{21} W/cm^{2}. High-resolution spectral analysis of x-ray emission reveals uniform heating up to 3.0 keV over 1 μm depths. Particle-in-cell simulations indicate the production of a uniformly heated keV plasma to depths of 2 μm. The significant bulk heating and presence of highly ionized ions deep within the target are attributed to the few MeV hot electrons that become trapped and undergo refluxing within the target sheath fields. These conditions enabled the differentiation of atomic physics models of ionization potential depression in high-energy-density environments.
Collapse
Affiliation(s)
- N F Beier
- Department of Electrical and Computer Engineering, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
- STROBE, NSF Science and Technology Center, University of California, Irvine, California 92617, USA
| | - H Allison
- STROBE, NSF Science and Technology Center, University of California, Irvine, California 92617, USA
| | - P Efthimion
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08536, USA
| | - K A Flippo
- Los Alamos National Laboratory, P.O. Box 1163, Los Alamos, New Mexico 87545, USA
| | - L Gao
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08536, USA
| | - S B Hansen
- Sandia National Laboratories, Albuquerque, New Mexico 87185, USA
| | - K Hill
- Princeton Plasma Physics Laboratory, Princeton, New Jersey 08536, USA
| | - R Hollinger
- Department of Electrical and Computer Engineering, Colorado State University, Fort Collins, Colorado 80521, USA
| | - M Logantha
- STROBE, NSF Science and Technology Center, University of California, Irvine, California 92617, USA
| | - Y Musthafa
- STROBE, NSF Science and Technology Center, University of California, Irvine, California 92617, USA
| | - R Nedbailo
- Department of Electrical and Computer Engineering, Colorado State University, Fort Collins, Colorado 80521, USA
| | - V Senthilkumaran
- Department of Electrical and Computer Engineering, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| | - R Shepherd
- Lawrence Livermore National Laboratory, Livermore, California 94550, USA
| | - V N Shlyaptsev
- Department of Electrical and Computer Engineering, Colorado State University, Fort Collins, Colorado 80521, USA
| | - H Song
- Department of Electrical and Computer Engineering, Colorado State University, Fort Collins, Colorado 80521, USA
| | - S Wang
- Department of Electrical and Computer Engineering, Colorado State University, Fort Collins, Colorado 80521, USA
| | - F Dollar
- STROBE, NSF Science and Technology Center, University of California, Irvine, California 92617, USA
| | - J J Rocca
- Department of Electrical and Computer Engineering, Colorado State University, Fort Collins, Colorado 80521, USA
- Department of Physics, Colorado State University, Fort Collins, Colorado 80521, USA
| | - A E Hussein
- Department of Electrical and Computer Engineering, University of Alberta, Edmonton, Alberta T6G 2R3, Canada
| |
Collapse
|
19
|
Rai PK, Sonne C, Song H, Kim KH. The effects of COVID-19 transmission on environmental sustainability and human health: Paving the way to ensure its sustainable management. Sci Total Environ 2022; 838:156039. [PMID: 35595144 PMCID: PMC9113776 DOI: 10.1016/j.scitotenv.2022.156039] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 04/01/2022] [Revised: 05/02/2022] [Accepted: 05/14/2022] [Indexed: 05/02/2023]
Abstract
The transmission dynamics and health risks of coronavirus disease 2019 (COVID-19) pandemic are inextricably linked to ineract with environment, climate, air pollution, and meteorological conditions. The spread of COVID-19 infection can thus perturb the 'planetary health' and livelihood by exerting impacts on the temporal and spatial variabilities of environmental pollution. Prioritization of COVID-19 by the health-care sector has been posing a serious threat to economic progress while undermining the efforts to meet the United Nations' Sustainable Development Goals (SDGs) for environmental sustainability. Here, we review the multifaceted effects of COVID-19 with respect to environmental quality, climatic variables, SDGs, energy resilience, and sustainability programs. It is well perceived that COVID-19 may have long-lasting and profound effects on socio-economic systems, food security, livelihoods, and the 'nexus' indicators. To seek for the solution of these problems, consensus can be drawn to establish and ensure a sound health-care system, a sustainable environment, and a circular bioeconomy. A holistic analysis of COVID-19's effects on multiple sectors should help develop nature-based solutions, cleaner technologies, and green economic recovery plans to help maintain environmental sustainability, ecosystem resilience, and planetary health.
Collapse
Affiliation(s)
- Prabhat Kumar Rai
- Phyto-Technologies and Plant Invasion Lab, Department of Environmental Science, School of Earth Sciences and Natural Resources Management, Mizoram University, Aizawl, Mizoram, India
| | - C Sonne
- Department of Ecoscience, Arctic Research Centre, Aarhus University, Frederiksborgvej 399, DK-4000 Roskilde, Denmark
| | - H Song
- Department of Environment and Energy, Sejong University, Seoul 05006, Republic of Korea
| | - Ki-Hyun Kim
- Department of Civil and Environmental Engineering, Hanyang University, 222 Wangsimni-Ro, Seoul 04763, Republic of Korea.
| |
Collapse
|
20
|
Mou YK, Ren C, Li YM, Yu GH, Zheng GB, Song H, Lu CX, Tian RX, Song XC. [Correlation analysis of clock genes and MEN2 medullary thyroid carcinoma]. Zhonghua Er Bi Yan Hou Tou Jing Wai Ke Za Zhi 2022; 57:1079-1086. [PMID: 36177562 DOI: 10.3760/cma.j.cn115330-20211225-00822] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/16/2023]
Abstract
Objective: To investigate the correlation between CLOCK and BMAL1 genes and MEN2 medullary thyroid carcinoma (MTC). Methods: Thirteen cases with MEN2 MTC and thirteen cases with non-MEN2 MTC were selected who were treated in the Yantai Yuhuangding Hospital between January 2013 and September 2021. Clinical indicators such as blood calcitonin level, tumor diameter and metastatic lymph node of patients were collected. The expression differences of CLOCK and BMAL1 between MEN2 MTC and para-carcinoma tissue as well as between MEN2 MTC and non-MEN2 MTC were detected by immunohistochemistry and qPCR. The correlation between lymph node metastasis and CLOCK or BMAL1 expression was analyzed. Protein-protein interaction (PPI) network analysis combined with qPCR and correlation analysis was used to explore the expression regulation relationship between RET and circadian clock genes. The rhythm disorder of MEN2 cells was verified by lipopolysaccharide cell stimulation experiment after dexamethasone rhythm synchronization. Results: MEN2 MTC exhibited typical RET gene mutation. The mean blood calcitonin level, the tumor diameter and the number of metastatic lymph nodes of patients with MEN2 MTC were higher than those of patients with non-MEN2 MTC (t value was 2.76, 2.53, 2.26, all P<0.05). Immunohistochemical results showed that the expression levels of CLOCK and BMAL1 in MEN2 MTC were higher than those in non-MEN2 MTC, while negatively expressed in para-cancerous thyroid follicle. qPCR displayed that the expression of CLOCK gene in cancer tissues was higher than that in non-MEN2 MTC and para-cancerous tissues (t value was 2.68 and 2.86, all P<0.05); the expression of BMAL1 gene in MEN2 MTC was higher than that in non-MEN2 MTC and para-cancerous tissues (t value was 2.21 and 2.35, all P<0.05). Correlation analysis showed that the expression levels of CLOCK and BMAL1 genes were positively correlated with the number of lymph node metastases in patients with MEN2 MTC (r=0.65, P<0.001; r=0.52, P=0.005). PPI network analysis indicated that the expression of CLOCK gene was positively correlated with the abnormal expression of RET gene (r=0.96, P<0.001). With lipopolysaccharide to stimulate cultured cells in vitro after dexamethasone rhythm synchronization, the expressions of CLOCK and BMAL1 in MEN2 MTC cells (0.47±0.22 and 2.60±1.48) at 12 hours of synchronization were significantly lower than those in para-cancerous tissues (1.70±1.62 and 8.23±2.52), the difference was statistically significant(t=5.04, P=0.007; t=3.34, P=0.029). Conclusion: CLOCK and BMAL1 are correlated with the occurrence and development of MEN2 MTC, and may be potential targets for the development of new therapeutic strategies for MEN2 MTC.
Collapse
Affiliation(s)
- Y K Mou
- Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai 264000, China Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai 264000, China State Key Laboratory of Oncology in South China, Guangzhou 510000, China
| | - C Ren
- Taishan Scholar Laboratory, Yantai Yuhuangding Hospital, Qingdao University, Yantai 264000, China Department of Neurology, Yantai Yuhuangding Hospital, Qingdao University, Yantai 264000, China
| | - Y M Li
- Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai 264000, China Taishan Scholar Laboratory, Yantai Yuhuangding Hospital, Qingdao University, Yantai 264000, China
| | - G H Yu
- Department of Pathology, Yantai Yuhuangding Hospital, Qingdao University, Yantai 264000, China
| | - G B Zheng
- Taishan Scholar Laboratory, Yantai Yuhuangding Hospital, Qingdao University, Yantai 264000, China Department of Thyroid Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai 264000, China
| | - H Song
- Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai 264000, China
| | - C X Lu
- Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai 264000, China
| | - R X Tian
- Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai 264000, China
| | - X C Song
- Department of Otorhinolaryngology, Head and Neck Surgery, Yantai Yuhuangding Hospital, Qingdao University, Yantai 264000, China Shandong Provincial Clinical Research Center for Otorhinolaryngologic Diseases, Yantai 264000, China Taishan Scholar Laboratory, Yantai Yuhuangding Hospital, Qingdao University, Yantai 264000, China
| |
Collapse
|
21
|
Kim S, Park G, Kim S, Song S, Song H, Ryu J, Park S, Pereira S, Paeng K, Ock CY. 1706P Artificial intelligence-powered tumor purity assessment from H&E whole slide images associates with variant allele frequency of somatic mutations across 23 cancer types in TCGA cohorts. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1784] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022] Open
|
22
|
Cho S, Lim Y, Cho S, Kim S, Park G, Song S, Song H, Park S, Ma M, Jung W, Paeng K, Ock CY, Cho E, Song S. 155P Artificial Intelligence (AI) - powered human epidermal growth factor receptor-2 (HER2) and tumor-infiltrating lymphocytes (TIL) analysis for HER2-positive early breast cancer patients treated with HER2-targeted neoadjuvant chemotherapy (NAC). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.190] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022] Open
|
23
|
Cho HG, Kim S, Choi S, Cho S, Jung W, Kim S, Park G, Song S, Pereira S, Song H, Park S, Mostafavi M, Paeng K, Ock CY. 900P AI-powered analyzer reveals enrichment of intra-tumoral tumor-infiltrating lymphocytes in high-grade neuroendocrine neoplasms. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022] Open
|
24
|
Zhu J, Chen W, Hu Y, Qu Y, Yang H, Zeng Y, Hou C, Ge F, Zhou Z, Song H. Physical activity patterns, genetic susceptibility, and risk of hip/knee osteoarthritis: a prospective cohort study based on the UK Biobank. Osteoarthritis Cartilage 2022; 30:1079-1090. [PMID: 35504554 DOI: 10.1016/j.joca.2022.04.004] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/25/2021] [Revised: 04/04/2022] [Accepted: 04/25/2022] [Indexed: 02/02/2023]
Abstract
OBJECTIVES The effect of physical activity on hip/knee osteoarthritis (OA) and how it varies by genetic susceptibility to OA remains inconclusive. METHODS In a cohort study of UK Biobank, 436,166 OA-free participants were recruited in 2006-2010 and followed for knee/hip OA until the end of 2020. 28 physical activity-related items were collected at baseline. Cox regression was used to estimate associations between physical activity behaviors, as well as major activity patterns (i.e., significant principal components[PCs] identified by principal component analysis), and risk of OA, adjusting for multiple confounders. We further stratified the analyses by polygenic risk score (PRS) for OA to examine the impact of genetic susceptibility to OA on the studied association. RESULTS During a mean follow-up of 11.15 years, 13,227 hip and 21,119 knee OA cases were identified. 19, out of 28, studied items showed associations with increased OA risk. Compared with low adherence group(<1st tertile of PC score for each pattern), individuals with high adherence to five identified patterns were associated with increased risk of OA. The moderate adherence to "strenuous sports"(HR = 0.93, 95%CI: 0.89-0.97) and "walking for pleasure"(HR = 0.93, 95%CI: 0.89-0.98) patterns was associated with reduced OA. Similar risk patterns were obtained in the stratified analysis by PRS levels for OA. CONCLUSION High intensity of most activity patterns were associated with increased OA. However, a protective effect was suggested for moderate adherence to patterns of "strenuous sports" and "walking for pleasure" that consistent across different genetic susceptibilities, underscoring the potential benefits of moderate-intensity physical activity on OA.
Collapse
Affiliation(s)
- J Zhu
- Department of Orthopedics, Orthopedic Research Institute, and West China Biomedical Big Data Center, West China Hospital, Sichuan University, Chengdu 610041, China
| | - W Chen
- Division of Nephrology, Kidney Research Institute, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, Sichuan University, Chengdu, China; West China Biomedical Big Data Center, West China Hospital, Sichuan University, Chengdu, China; Med-X Center for Informatics, Sichuan University, Chengdu, China
| | - Y Hu
- West China Biomedical Big Data Center, West China Hospital, Sichuan University, Chengdu, China; Med-X Center for Informatics, Sichuan University, Chengdu, China
| | - Y Qu
- West China Biomedical Big Data Center, West China Hospital, Sichuan University, Chengdu, China; Med-X Center for Informatics, Sichuan University, Chengdu, China
| | - H Yang
- West China Biomedical Big Data Center, West China Hospital, Sichuan University, Chengdu, China; Med-X Center for Informatics, Sichuan University, Chengdu, China
| | - Y Zeng
- West China Biomedical Big Data Center, West China Hospital, Sichuan University, Chengdu, China; Med-X Center for Informatics, Sichuan University, Chengdu, China
| | - C Hou
- West China Biomedical Big Data Center, West China Hospital, Sichuan University, Chengdu, China; Med-X Center for Informatics, Sichuan University, Chengdu, China
| | - F Ge
- West China Biomedical Big Data Center, West China Hospital, Sichuan University, Chengdu, China; Med-X Center for Informatics, Sichuan University, Chengdu, China
| | - Z Zhou
- Department of Orthopedics, Orthopedic Research Institute, West China Hospital, Sichuan University, Chengdu 610041, China.
| | - H Song
- West China Biomedical Big Data Center, West China Hospital, Sichuan University, Chengdu, China; Med-X Center for Informatics, Sichuan University, Chengdu, China; Center of Public Health Sciences, Faculty of Medicine, University of Iceland, Reykjavík, Iceland.
| |
Collapse
|
25
|
Luan X, Gao Z, Sun J, Chen G, Yan S, Yu H, Song H, Yao J, Song P. Feasibility of an ultra-low dose contrast media protocol for coronary CT angiography. Clin Radiol 2022; 77:e705-e710. [PMID: 35778294 DOI: 10.1016/j.crad.2022.05.029] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/31/2021] [Revised: 05/30/2022] [Accepted: 05/30/2022] [Indexed: 11/25/2022]
Abstract
AIM To evaluate the feasibility of an ultra-low volume contrast media (CM) protocol for coronary computed tomography angiography (CTA). MATERIALS AND METHODS In total, 214 patients receiving coronary CTA were enrolled prospectively and divided into group A (n=107) receiving a conventional dose of CM and group B (n=107) receiving an ultra-low dose. CT values of the right coronary artery (RCA), left anterior descending artery (LAD), and left circumflex artery (LCX) were measured and radiation doses recorded. The image quality was compared between the groups. Changes in renal function indices and proteinuria before, 24, and 72 hours after coronary CTA among those with chronic kidney disease (CKD) were also assessed. RESULTS There were significant differences in CT values and radiation doses between groups A and B. In group A, the average RCA, LAD, and LCX CT values were 412.5 ± 79.2, 423.5 ± 73.7, and 422.0 ± 88.1 HU, respectively. In group B, the average RCA, LAD, and LCX CT values were 275.2 ± 16.2, 277.8 ± 16.4, and 278.9 ± 16.5 HU, respectively. The radiation dose in the ultra-low protocol recipients (118.70 ± 18.52 mGy·cm) was significantly lower than that used in conventional coronary CTA (131.75 ± 20.96 mGy·cm). The image quality of group B was comparable to that of group A, satisfying the diagnostic requirement. In patients with mild CKD, there were no significant differences in renal functions after coronary CTA. CONCLUSION An ultra-low CM protocol was established for coronary CTA, providing comparable image quality and diagnostic yields but significantly lower radiation dose compared with a conventional protocol. This new protocol might be applicable to patients with mild CKD.
Collapse
Affiliation(s)
- X Luan
- Weifang Medical University, Weifang 261053, China; Jinan Central Hospital, Jinan 250013, China
| | - Z Gao
- Department of Radiology, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, China; Department of Radiology, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250013, China
| | - J Sun
- Department of Radiology, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, China; Department of Radiology, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250013, China
| | - G Chen
- Department of Radiology, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, China; Department of Radiology, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250013, China
| | - S Yan
- Department of Radiology, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, China
| | - H Yu
- Department of Radiology, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, China
| | - H Song
- The Institute for Tissue Engineering and Regenerative Medicine, The Liaocheng University/liaocheng People's Hospital, Liaocheng 252000, China
| | - J Yao
- Department of Radiology, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, China; Department of Radiology, Provincial Hospital Affiliated to Shandong First Medical University, Jinan 250021, China
| | - P Song
- Department of Radiology, Central Hospital Affiliated to Shandong First Medical University, Jinan 250013, China; Department of Radiology, Jinan Central Hospital, Cheeloo College of Medicine, Shandong University, Jinan 250013, China.
| |
Collapse
|
26
|
Song E, Wang X, Philipson B, Zhang Q, Thokala R, Binder Z, O’Rourke D, Song H, Milone M. Immunotherapy: THE IAP INHIBITOR BIRINAPANT ENHANCES CAR-T CELL THERAPY FOR GLIOBLASTOMA BY OVERCOMING ANTIGEN HETEROGENEITY. Cytotherapy 2022. [DOI: 10.1016/s1465-3249(22)00334-6] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
|
27
|
Aaltonen T, Amerio S, Amidei D, Anastassov A, Annovi A, Antos J, Apollinari G, Appel JA, Arisawa T, Artikov A, Asaadi J, Ashmanskas W, Auerbach B, Aurisano A, Azfar F, Badgett W, Bae T, Barbaro-Galtieri A, Barnes VE, Barnett BA, Barria P, Bartos P, Bauce M, Bedeschi F, Behari S, Bellettini G, Bellinger J, Benjamin D, Beretvas A, Bhatti A, Bland KR, Blumenfeld B, Bocci A, Bodek A, Bortoletto D, Boudreau J, Boveia A, Brigliadori L, Bromberg C, Brucken E, Budagov J, Budd HS, Burkett K, Busetto G, Bussey P, Butti P, Buzatu A, Calamba A, Camarda S, Campanelli M, Carls B, Carlsmith D, Carosi R, Carrillo S, Casal B, Casarsa M, Castro A, Catastini P, Cauz D, Cavaliere V, Cerri A, Cerrito L, Chen YC, Chertok M, Chiarelli G, Chlachidze G, Cho K, Chokheli D, Clark A, Clarke C, Convery ME, Conway J, Corbo M, Cordelli M, Cox CA, Cox DJ, Cremonesi M, Cruz D, Cuevas J, Culbertson R, d'Ascenzo N, Datta M, de Barbaro P, Demortier L, Deninno M, D'Errico M, Devoto F, Di Canto A, Di Ruzza B, Dittmann JR, Donati S, D'Onofrio M, Dorigo M, Driutti A, Ebina K, Edgar R, Elagin A, Erbacher R, Errede S, Esham B, Farrington S, Fernández Ramos JP, Field R, Flanagan G, Forrest R, Franklin M, Freeman JC, Frisch H, Funakoshi Y, Galloni C, Garfinkel AF, Garosi P, Gerberich H, Gerchtein E, Giagu S, Giakoumopoulou V, Gibson K, Ginsburg CM, Giokaris N, Giromini P, Glagolev V, Glenzinski D, Gold M, Goldin D, Golossanov A, Gomez G, Gomez-Ceballos G, Goncharov M, González López O, Gorelov I, Goshaw AT, Goulianos K, Gramellini E, Grosso-Pilcher C, Guimaraes da Costa J, Hahn SR, Han JY, Happacher F, Hara K, Hare M, Harr RF, Harrington-Taber T, Hatakeyama K, Hays C, Heinrich J, Herndon M, Hocker A, Hong Z, Hopkins W, Hou S, Hughes RE, Husemann U, Hussein M, Huston J, Introzzi G, Iori M, Ivanov A, James E, Jang D, Jayatilaka B, Jeon EJ, Jindariani S, Jones M, Joo KK, Jun SY, Junk TR, Kambeitz M, Kamon T, Karchin PE, Kasmi A, Kato Y, Ketchum W, Keung J, Kilminster B, Kim DH, Kim HS, Kim JE, Kim MJ, Kim SH, Kim SB, Kim YJ, Kim YK, Kimura N, Kirby M, Kondo K, Kong DJ, Konigsberg J, Kotwal AV, Kreps M, Kroll J, Kruse M, Kuhr T, Kurata M, Laasanen AT, Lammel S, Lancaster M, Lannon K, Latino G, Lee HS, Lee JS, Leo S, Leone S, Lewis JD, Limosani A, Lipeles E, Lister A, Liu Q, Liu T, Lockwitz S, Loginov A, Lucchesi D, Lucà A, Lueck J, Lujan P, Lukens P, Lungu G, Lys J, Lysak R, Madrak R, Maestro P, Malik S, Manca G, Manousakis-Katsikakis A, Marchese L, Margaroli F, Marino P, Matera K, Mattson ME, Mazzacane A, Mazzanti P, McNulty R, Mehta A, Mehtala P, Menzione A, Mesropian C, Miao T, Michielin E, Mietlicki D, Mitra A, Miyake H, Moed S, Moggi N, Moon CS, Moore R, Morello MJ, Mukherjee A, Muller T, Murat P, Mussini M, Nachtman J, Nagai Y, Naganoma J, Nakano I, Napier A, Nett J, Nigmanov T, Nodulman L, Noh SY, Norniella O, Oakes L, Oh SH, Oh YD, Okusawa T, Orava R, Ortolan L, Pagliarone C, Palencia E, Palni P, Papadimitriou V, Parker W, Pauletta G, Paulini M, Paus C, Phillips TJ, Piacentino G, Pianori E, Pilot J, Pitts K, Plager C, Pondrom L, Poprocki S, Potamianos K, Pranko A, Prokoshin F, Ptohos F, Punzi G, Redondo Fernández I, Renton P, Rescigno M, Rimondi F, Ristori L, Robson A, Rodriguez T, Rolli S, Ronzani M, Roser R, Rosner JL, Ruffini F, Ruiz A, Russ J, Rusu V, Sakumoto WK, Sakurai Y, Santi L, Sato K, Saveliev V, Savoy-Navarro A, Schlabach P, Schmidt EE, Schwarz T, Scodellaro L, Scuri F, Seidel S, Seiya Y, Semenov A, Sforza F, Shalhout SZ, Shears T, Shepard PF, Shimojima M, Shochet M, Shreyber-Tecker I, Simonenko A, Sliwa K, Smith JR, Snider FD, Song H, Sorin V, St Denis R, Stancari M, Stentz D, Strologas J, Sudo Y, Sukhanov A, Suslov I, Takemasa K, Takeuchi Y, Tang J, Tecchio M, Teng PK, Thom J, Thomson E, Thukral V, Toback D, Tokar S, Tollefson K, Tomura T, Torre S, Torretta D, Totaro P, Trovato M, Ukegawa F, Uozumi S, Vázquez F, Velev G, Vellidis K, Vernieri C, Vidal M, Vilar R, Vizán J, Vogel M, Volpi G, Wagner P, Wallny R, Wang SM, Waters D, Wester WC, Whiteson D, Wicklund AB, Wilbur S, Williams HH, Wilson JS, Wilson P, Winer BL, Wittich P, Wolbers S, Wolfmeister H, Wright T, Wu X, Wu Z, Yamamoto K, Yamato D, Yang T, Yang UK, Yang YC, Yao WM, Yeh GP, Yi K, Yoh J, Yorita K, Yoshida T, Yu GB, Yu I, Zanetti AM, Zeng Y, Zhou C, Zucchelli S. High-precision measurement of the W boson mass with the CDF II detector. Science 2022; 376:170-176. [PMID: 35389814 DOI: 10.1126/science.abk1781] [Citation(s) in RCA: 77] [Impact Index Per Article: 38.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/02/2022]
Abstract
The mass of the W boson, a mediator of the weak force between elementary particles, is tightly constrained by the symmetries of the standard model of particle physics. The Higgs boson was the last missing component of the model. After observation of the Higgs boson, a measurement of the W boson mass provides a stringent test of the model. We measure the W boson mass, MW, using data corresponding to 8.8 inverse femtobarns of integrated luminosity collected in proton-antiproton collisions at a 1.96 tera-electron volt center-of-mass energy with the CDF II detector at the Fermilab Tevatron collider. A sample of approximately 4 million W boson candidates is used to obtain [Formula: see text], the precision of which exceeds that of all previous measurements combined (stat, statistical uncertainty; syst, systematic uncertainty; MeV, mega-electron volts; c, speed of light in a vacuum). This measurement is in significant tension with the standard model expectation.
Collapse
Affiliation(s)
| | - T Aaltonen
- Division of High Energy Physics, Department of Physics, University of Helsinki, FIN-00014, Helsinki, Finland.,Helsinki Institute of Physics, FIN-00014, Helsinki, Finland
| | - S Amerio
- Istituto Nazionale di Fisica Nucleare, Sezione di Padova, I-35131 Padova, Italy.,University of Padova, I-35131 Padova, Italy
| | - D Amidei
- University of Michigan, Ann Arbor, MI 48109, USA
| | - A Anastassov
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - A Annovi
- Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - J Antos
- Comenius University, 842 48 Bratislava, Slovakia.,Institute of Experimental Physics, 040 01 Kosice, Slovakia
| | - G Apollinari
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - J A Appel
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | | | - A Artikov
- Joint Institute for Nuclear Research, Dubna RU-141980, Russia
| | - J Asaadi
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA
| | - W Ashmanskas
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - B Auerbach
- Argonne National Laboratory, Argonne, IL 60439, USA
| | - A Aurisano
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA
| | - F Azfar
- University of Oxford, Oxford OX1 3RH, UK
| | - W Badgett
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - T Bae
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - A Barbaro-Galtieri
- Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
| | - V E Barnes
- Purdue University, West Lafayette, IN 47907, USA
| | - B A Barnett
- The Johns Hopkins University, Baltimore, MD 21218, USA
| | - P Barria
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Siena, I-53100 Siena, Italy
| | - P Bartos
- Comenius University, 842 48 Bratislava, Slovakia.,Institute of Experimental Physics, 040 01 Kosice, Slovakia
| | - M Bauce
- Istituto Nazionale di Fisica Nucleare, Sezione di Padova, I-35131 Padova, Italy.,University of Padova, I-35131 Padova, Italy
| | - F Bedeschi
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy
| | - S Behari
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - G Bellettini
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Pisa, I-56126 Pisa, Italy
| | - J Bellinger
- University of Wisconsin-Madison, Madison, WI 53706, USA
| | | | - A Beretvas
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - A Bhatti
- The Rockefeller University, New York, NY 10065, USA
| | - K R Bland
- Baylor University, Waco, TX 76798, USA
| | - B Blumenfeld
- The Johns Hopkins University, Baltimore, MD 21218, USA
| | - A Bocci
- Duke University, Durham, NC 27708, USA
| | - A Bodek
- University of Rochester, Rochester, NY 14627, USA
| | - D Bortoletto
- Purdue University, West Lafayette, IN 47907, USA
| | - J Boudreau
- University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - A Boveia
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | - L Brigliadori
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy.,University of Bologna, I-40127 Bologna, Italy
| | - C Bromberg
- Michigan State University, East Lansing, MI 48824, USA
| | - E Brucken
- Division of High Energy Physics, Department of Physics, University of Helsinki, FIN-00014, Helsinki, Finland.,Helsinki Institute of Physics, FIN-00014, Helsinki, Finland
| | - J Budagov
- Joint Institute for Nuclear Research, Dubna RU-141980, Russia
| | - H S Budd
- University of Rochester, Rochester, NY 14627, USA
| | - K Burkett
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - G Busetto
- Istituto Nazionale di Fisica Nucleare, Sezione di Padova, I-35131 Padova, Italy.,University of Padova, I-35131 Padova, Italy
| | - P Bussey
- Glasgow University, Glasgow G12 8QQ, UK
| | - P Butti
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Pisa, I-56126 Pisa, Italy
| | - A Buzatu
- Glasgow University, Glasgow G12 8QQ, UK
| | - A Calamba
- Carnegie Mellon University, Pittsburgh, PA 15213, USA
| | - S Camarda
- Institut de Fisica d'Altes Energies, ICREA, Universitat Autonoma de Barcelona, E-08193 Bellaterra (Barcelona), Spain
| | | | - B Carls
- University of Illinois, Urbana, IL 61801, USA
| | - D Carlsmith
- University of Wisconsin-Madison, Madison, WI 53706, USA
| | - R Carosi
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy
| | - S Carrillo
- University of Florida, Gainesville, FL 32611, USA
| | - B Casal
- Instituto de Fisica de Cantabria, CSIC-University of Cantabria, 39005 Santander, Spain
| | - M Casarsa
- Istituto Nazionale di Fisica Nucleare Trieste, I-34127 Trieste, Italy
| | - A Castro
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy.,University of Bologna, I-40127 Bologna, Italy
| | - P Catastini
- Harvard University, Cambridge, MA 02138, USA
| | - D Cauz
- Istituto Nazionale di Fisica Nucleare Trieste, I-34127 Trieste, Italy.,Gruppo Collegato di Udine, I-33100 Udine, Italy.,University of Udine, I-33100 Udine, Italy
| | - V Cavaliere
- University of Illinois, Urbana, IL 61801, USA
| | - A Cerri
- Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
| | - L Cerrito
- University College London, London WC1E 6BT, UK
| | - Y C Chen
- Institute of Physics, Academia Sinica, Taipei, Taiwan 11529, Republic of China
| | - M Chertok
- University of California, Davis, Davis, CA 95616, USA
| | - G Chiarelli
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy
| | - G Chlachidze
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - K Cho
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - D Chokheli
- Joint Institute for Nuclear Research, Dubna RU-141980, Russia
| | - A Clark
- University of Geneva, CH-1211 Geneva 4, Switzerland
| | - C Clarke
- Wayne State University, Detroit, MI 48201, USA
| | - M E Convery
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - J Conway
- University of California, Davis, Davis, CA 95616, USA
| | - M Corbo
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - M Cordelli
- Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - C A Cox
- University of California, Davis, Davis, CA 95616, USA
| | - D J Cox
- University of California, Davis, Davis, CA 95616, USA
| | - M Cremonesi
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy
| | - D Cruz
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA
| | - J Cuevas
- Instituto de Fisica de Cantabria, CSIC-University of Cantabria, 39005 Santander, Spain
| | - R Culbertson
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - N d'Ascenzo
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - M Datta
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - P de Barbaro
- University of Rochester, Rochester, NY 14627, USA
| | - L Demortier
- The Rockefeller University, New York, NY 10065, USA
| | - M Deninno
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy
| | - M D'Errico
- Istituto Nazionale di Fisica Nucleare, Sezione di Padova, I-35131 Padova, Italy.,University of Padova, I-35131 Padova, Italy
| | - F Devoto
- Division of High Energy Physics, Department of Physics, University of Helsinki, FIN-00014, Helsinki, Finland.,Helsinki Institute of Physics, FIN-00014, Helsinki, Finland
| | - A Di Canto
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Pisa, I-56126 Pisa, Italy
| | - B Di Ruzza
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | | | - S Donati
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Pisa, I-56126 Pisa, Italy
| | - M D'Onofrio
- University of Liverpool, Liverpool L69 7ZE, UK
| | - M Dorigo
- Istituto Nazionale di Fisica Nucleare Trieste, I-34127 Trieste, Italy.,University of Trieste, I-34127 Trieste, Italy
| | - A Driutti
- Istituto Nazionale di Fisica Nucleare Trieste, I-34127 Trieste, Italy.,Gruppo Collegato di Udine, I-33100 Udine, Italy.,University of Udine, I-33100 Udine, Italy
| | - K Ebina
- Waseda University, Tokyo 169, Japan
| | - R Edgar
- University of Michigan, Ann Arbor, MI 48109, USA
| | - A Elagin
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | - R Erbacher
- University of California, Davis, Davis, CA 95616, USA
| | - S Errede
- University of Illinois, Urbana, IL 61801, USA
| | - B Esham
- University of Illinois, Urbana, IL 61801, USA
| | | | - J P Fernández Ramos
- Centro de Investigaciones Energeticas Medioambientales y Tecnologicas, E-28040 Madrid, Spain
| | - R Field
- University of Florida, Gainesville, FL 32611, USA
| | - G Flanagan
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - R Forrest
- University of California, Davis, Davis, CA 95616, USA
| | - M Franklin
- Harvard University, Cambridge, MA 02138, USA
| | - J C Freeman
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - H Frisch
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | | | - C Galloni
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Pisa, I-56126 Pisa, Italy
| | | | - P Garosi
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Siena, I-53100 Siena, Italy
| | - H Gerberich
- University of Illinois, Urbana, IL 61801, USA
| | - E Gerchtein
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - S Giagu
- Istituto Nazionale di Fisica Nucleare, Sezione di Roma 1, I-00185 Roma, Italy
| | - V Giakoumopoulou
- National and Kapodistrian University of Athens, 157 71 Athens, Greece
| | - K Gibson
- University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - C M Ginsburg
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - N Giokaris
- National and Kapodistrian University of Athens, 157 71 Athens, Greece
| | - P Giromini
- Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - V Glagolev
- Joint Institute for Nuclear Research, Dubna RU-141980, Russia
| | - D Glenzinski
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - M Gold
- University of New Mexico, Albuquerque, NM 87131, USA
| | - D Goldin
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA
| | - A Golossanov
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - G Gomez
- Instituto de Fisica de Cantabria, CSIC-University of Cantabria, 39005 Santander, Spain
| | | | - M Goncharov
- Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | - O González López
- Centro de Investigaciones Energeticas Medioambientales y Tecnologicas, E-28040 Madrid, Spain
| | - I Gorelov
- University of New Mexico, Albuquerque, NM 87131, USA
| | | | - K Goulianos
- The Rockefeller University, New York, NY 10065, USA
| | - E Gramellini
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy
| | - C Grosso-Pilcher
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | | | - S R Hahn
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - J Y Han
- University of Rochester, Rochester, NY 14627, USA
| | - F Happacher
- Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - K Hara
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - M Hare
- Tufts University, Medford, MA 02155, USA
| | - R F Harr
- Wayne State University, Detroit, MI 48201, USA
| | | | | | - C Hays
- University of Oxford, Oxford OX1 3RH, UK
| | - J Heinrich
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - M Herndon
- University of Wisconsin-Madison, Madison, WI 53706, USA
| | - A Hocker
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - Z Hong
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA
| | - W Hopkins
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - S Hou
- Institute of Physics, Academia Sinica, Taipei, Taiwan 11529, Republic of China
| | - R E Hughes
- The Ohio State University, Columbus, OH 43210, USA
| | - U Husemann
- Yale University, New Haven, CT 06520, USA
| | - M Hussein
- Michigan State University, East Lansing, MI 48824, USA
| | - J Huston
- Michigan State University, East Lansing, MI 48824, USA
| | - G Introzzi
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,Istituto Nazionale di Fisica Nucleare Pavia, I-27100 Pavia, Italy.,University of Pavia, I-27100 Pavia, Italy
| | - M Iori
- Istituto Nazionale di Fisica Nucleare, Sezione di Roma 1, I-00185 Roma, Italy.,Sapienza Università di Roma, I-00185 Roma, Italy
| | - A Ivanov
- University of California, Davis, Davis, CA 95616, USA
| | - E James
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - D Jang
- Carnegie Mellon University, Pittsburgh, PA 15213, USA
| | - B Jayatilaka
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - E J Jeon
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - S Jindariani
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - M Jones
- Purdue University, West Lafayette, IN 47907, USA
| | - K K Joo
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - S Y Jun
- Carnegie Mellon University, Pittsburgh, PA 15213, USA
| | - T R Junk
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - M Kambeitz
- Institut für Experimentelle Kernphysik, Karlsruhe Institute of Technology, D-76131 Karlsruhe, Germany
| | - T Kamon
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA.,Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - P E Karchin
- Wayne State University, Detroit, MI 48201, USA
| | - A Kasmi
- Baylor University, Waco, TX 76798, USA
| | - Y Kato
- Osaka City University, Osaka 558-8585, Japan
| | - W Ketchum
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | - J Keung
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - B Kilminster
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - D H Kim
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - H S Kim
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - J E Kim
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - M J Kim
- Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - S H Kim
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - S B Kim
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - Y J Kim
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - Y K Kim
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | - N Kimura
- Waseda University, Tokyo 169, Japan
| | - M Kirby
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - K Kondo
- Waseda University, Tokyo 169, Japan
| | - D J Kong
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - J Konigsberg
- University of Florida, Gainesville, FL 32611, USA
| | | | - M Kreps
- Institut für Experimentelle Kernphysik, Karlsruhe Institute of Technology, D-76131 Karlsruhe, Germany
| | - J Kroll
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - M Kruse
- Duke University, Durham, NC 27708, USA
| | - T Kuhr
- Institut für Experimentelle Kernphysik, Karlsruhe Institute of Technology, D-76131 Karlsruhe, Germany
| | - M Kurata
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - A T Laasanen
- Purdue University, West Lafayette, IN 47907, USA
| | - S Lammel
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - M Lancaster
- University College London, London WC1E 6BT, UK
| | - K Lannon
- The Ohio State University, Columbus, OH 43210, USA
| | - G Latino
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Siena, I-53100 Siena, Italy
| | - H S Lee
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - J S Lee
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - S Leo
- University of Illinois, Urbana, IL 61801, USA
| | - S Leone
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy
| | - J D Lewis
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | | | - E Lipeles
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - A Lister
- University of Geneva, CH-1211 Geneva 4, Switzerland
| | - Q Liu
- Purdue University, West Lafayette, IN 47907, USA
| | - T Liu
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - S Lockwitz
- Yale University, New Haven, CT 06520, USA
| | - A Loginov
- Yale University, New Haven, CT 06520, USA
| | - D Lucchesi
- Istituto Nazionale di Fisica Nucleare, Sezione di Padova, I-35131 Padova, Italy.,University of Padova, I-35131 Padova, Italy
| | - A Lucà
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA.,Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - J Lueck
- Institut für Experimentelle Kernphysik, Karlsruhe Institute of Technology, D-76131 Karlsruhe, Germany
| | - P Lujan
- Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
| | - P Lukens
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - G Lungu
- The Rockefeller University, New York, NY 10065, USA
| | - J Lys
- Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
| | - R Lysak
- Comenius University, 842 48 Bratislava, Slovakia.,Institute of Experimental Physics, 040 01 Kosice, Slovakia
| | - R Madrak
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - P Maestro
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Siena, I-53100 Siena, Italy
| | - S Malik
- The Rockefeller University, New York, NY 10065, USA
| | - G Manca
- University of Liverpool, Liverpool L69 7ZE, UK
| | | | - L Marchese
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy
| | - F Margaroli
- Istituto Nazionale di Fisica Nucleare, Sezione di Roma 1, I-00185 Roma, Italy
| | - P Marino
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,Scuola Normale Superiore, I-56126 Pisa, Italy
| | - K Matera
- University of Illinois, Urbana, IL 61801, USA
| | - M E Mattson
- Wayne State University, Detroit, MI 48201, USA
| | - A Mazzacane
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - P Mazzanti
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy
| | - R McNulty
- University of Liverpool, Liverpool L69 7ZE, UK
| | - A Mehta
- University of Liverpool, Liverpool L69 7ZE, UK
| | - P Mehtala
- Division of High Energy Physics, Department of Physics, University of Helsinki, FIN-00014, Helsinki, Finland.,Helsinki Institute of Physics, FIN-00014, Helsinki, Finland
| | - A Menzione
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy
| | - C Mesropian
- The Rockefeller University, New York, NY 10065, USA
| | - T Miao
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - E Michielin
- Istituto Nazionale di Fisica Nucleare, Sezione di Padova, I-35131 Padova, Italy.,University of Padova, I-35131 Padova, Italy
| | - D Mietlicki
- University of Michigan, Ann Arbor, MI 48109, USA
| | - A Mitra
- Institute of Physics, Academia Sinica, Taipei, Taiwan 11529, Republic of China
| | - H Miyake
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - S Moed
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - N Moggi
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy
| | - C S Moon
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - R Moore
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - M J Morello
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,Scuola Normale Superiore, I-56126 Pisa, Italy
| | - A Mukherjee
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - Th Muller
- Institut für Experimentelle Kernphysik, Karlsruhe Institute of Technology, D-76131 Karlsruhe, Germany
| | - P Murat
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - M Mussini
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy.,University of Bologna, I-40127 Bologna, Italy
| | - J Nachtman
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - Y Nagai
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | | | - I Nakano
- Okayama University, Okayama 700-8530, Japan
| | - A Napier
- Tufts University, Medford, MA 02155, USA
| | - J Nett
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA
| | - T Nigmanov
- University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - L Nodulman
- Argonne National Laboratory, Argonne, IL 60439, USA
| | - S Y Noh
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - O Norniella
- University of Illinois, Urbana, IL 61801, USA
| | - L Oakes
- University of Oxford, Oxford OX1 3RH, UK
| | - S H Oh
- Duke University, Durham, NC 27708, USA
| | - Y D Oh
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - T Okusawa
- Osaka City University, Osaka 558-8585, Japan
| | - R Orava
- Division of High Energy Physics, Department of Physics, University of Helsinki, FIN-00014, Helsinki, Finland.,Helsinki Institute of Physics, FIN-00014, Helsinki, Finland
| | - L Ortolan
- Institut de Fisica d'Altes Energies, ICREA, Universitat Autonoma de Barcelona, E-08193 Bellaterra (Barcelona), Spain
| | - C Pagliarone
- Istituto Nazionale di Fisica Nucleare Trieste, I-34127 Trieste, Italy
| | - E Palencia
- Instituto de Fisica de Cantabria, CSIC-University of Cantabria, 39005 Santander, Spain
| | - P Palni
- University of New Mexico, Albuquerque, NM 87131, USA
| | - V Papadimitriou
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - W Parker
- University of Wisconsin-Madison, Madison, WI 53706, USA
| | - G Pauletta
- Istituto Nazionale di Fisica Nucleare Trieste, I-34127 Trieste, Italy.,Gruppo Collegato di Udine, I-33100 Udine, Italy.,University of Udine, I-33100 Udine, Italy
| | - M Paulini
- Carnegie Mellon University, Pittsburgh, PA 15213, USA
| | - C Paus
- Massachusetts Institute of Technology, Cambridge, MA 02139, USA
| | | | - G Piacentino
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - E Pianori
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - J Pilot
- University of California, Davis, Davis, CA 95616, USA
| | - K Pitts
- University of Illinois, Urbana, IL 61801, USA
| | - C Plager
- University of California, Los Angeles, Los Angeles, CA 90024, USA
| | - L Pondrom
- University of Wisconsin-Madison, Madison, WI 53706, USA
| | - S Poprocki
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - K Potamianos
- Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
| | - A Pranko
- Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
| | - F Prokoshin
- Joint Institute for Nuclear Research, Dubna RU-141980, Russia
| | - F Ptohos
- Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - G Punzi
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Pisa, I-56126 Pisa, Italy
| | - I Redondo Fernández
- Centro de Investigaciones Energeticas Medioambientales y Tecnologicas, E-28040 Madrid, Spain
| | - P Renton
- University of Oxford, Oxford OX1 3RH, UK
| | - M Rescigno
- Istituto Nazionale di Fisica Nucleare, Sezione di Roma 1, I-00185 Roma, Italy
| | - F Rimondi
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy
| | - L Ristori
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA.,Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy
| | - A Robson
- Glasgow University, Glasgow G12 8QQ, UK
| | - T Rodriguez
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - S Rolli
- Tufts University, Medford, MA 02155, USA
| | - M Ronzani
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Pisa, I-56126 Pisa, Italy
| | - R Roser
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - J L Rosner
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | - F Ruffini
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Siena, I-53100 Siena, Italy
| | - A Ruiz
- Instituto de Fisica de Cantabria, CSIC-University of Cantabria, 39005 Santander, Spain
| | - J Russ
- Carnegie Mellon University, Pittsburgh, PA 15213, USA
| | - V Rusu
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - W K Sakumoto
- University of Rochester, Rochester, NY 14627, USA
| | | | - L Santi
- Istituto Nazionale di Fisica Nucleare Trieste, I-34127 Trieste, Italy.,Gruppo Collegato di Udine, I-33100 Udine, Italy.,University of Udine, I-33100 Udine, Italy
| | - K Sato
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - V Saveliev
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - A Savoy-Navarro
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - P Schlabach
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - E E Schmidt
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - T Schwarz
- University of Michigan, Ann Arbor, MI 48109, USA
| | - L Scodellaro
- Instituto de Fisica de Cantabria, CSIC-University of Cantabria, 39005 Santander, Spain
| | - F Scuri
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy
| | - S Seidel
- University of New Mexico, Albuquerque, NM 87131, USA
| | - Y Seiya
- Osaka City University, Osaka 558-8585, Japan
| | - A Semenov
- Joint Institute for Nuclear Research, Dubna RU-141980, Russia
| | - F Sforza
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,University of Pisa, I-56126 Pisa, Italy
| | - S Z Shalhout
- University of California, Davis, Davis, CA 95616, USA
| | - T Shears
- University of Liverpool, Liverpool L69 7ZE, UK
| | - P F Shepard
- University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - M Shimojima
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - M Shochet
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | - I Shreyber-Tecker
- Institution for Theoretical and Experimental Physics, ITEP, Moscow 117259, Russia
| | - A Simonenko
- Joint Institute for Nuclear Research, Dubna RU-141980, Russia
| | - K Sliwa
- Tufts University, Medford, MA 02155, USA
| | - J R Smith
- University of California, Davis, Davis, CA 95616, USA
| | - F D Snider
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - H Song
- University of Pittsburgh, Pittsburgh, PA 15260, USA
| | - V Sorin
- Institut de Fisica d'Altes Energies, ICREA, Universitat Autonoma de Barcelona, E-08193 Bellaterra (Barcelona), Spain
| | | | - M Stancari
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - D Stentz
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - J Strologas
- University of New Mexico, Albuquerque, NM 87131, USA
| | - Y Sudo
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - A Sukhanov
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - I Suslov
- Joint Institute for Nuclear Research, Dubna RU-141980, Russia
| | - K Takemasa
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - Y Takeuchi
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - J Tang
- Enrico Fermi Institute, University of Chicago, Chicago, IL 60637, USA
| | - M Tecchio
- University of Michigan, Ann Arbor, MI 48109, USA
| | - P K Teng
- Institute of Physics, Academia Sinica, Taipei, Taiwan 11529, Republic of China
| | - J Thom
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - E Thomson
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - V Thukral
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA
| | - D Toback
- Mitchell Institute for Fundamental Physics and Astronomy, Texas A&M University, College Station, TX 77843, USA
| | - S Tokar
- Comenius University, 842 48 Bratislava, Slovakia.,Institute of Experimental Physics, 040 01 Kosice, Slovakia
| | - K Tollefson
- Michigan State University, East Lansing, MI 48824, USA
| | - T Tomura
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - S Torre
- Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - D Torretta
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - P Totaro
- Istituto Nazionale di Fisica Nucleare, Sezione di Padova, I-35131 Padova, Italy
| | - M Trovato
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,Scuola Normale Superiore, I-56126 Pisa, Italy
| | - F Ukegawa
- University of Tsukuba, Tsukuba, Ibaraki 305, Japan
| | - S Uozumi
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - F Vázquez
- University of Florida, Gainesville, FL 32611, USA
| | - G Velev
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - K Vellidis
- National and Kapodistrian University of Athens, 157 71 Athens, Greece
| | - C Vernieri
- Istituto Nazionale di Fisica Nucleare Pisa, I-56127 Pisa, Italy.,Scuola Normale Superiore, I-56126 Pisa, Italy
| | - M Vidal
- Purdue University, West Lafayette, IN 47907, USA
| | - R Vilar
- Instituto de Fisica de Cantabria, CSIC-University of Cantabria, 39005 Santander, Spain
| | - J Vizán
- Instituto de Fisica de Cantabria, CSIC-University of Cantabria, 39005 Santander, Spain
| | - M Vogel
- University of New Mexico, Albuquerque, NM 87131, USA
| | - G Volpi
- Laboratori Nazionali di Frascati, Istituto Nazionale di Fisica Nucleare, I-00044 Frascati, Italy
| | - P Wagner
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - R Wallny
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - S M Wang
- Institute of Physics, Academia Sinica, Taipei, Taiwan 11529, Republic of China
| | - D Waters
- University College London, London WC1E 6BT, UK
| | - W C Wester
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - D Whiteson
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - A B Wicklund
- Argonne National Laboratory, Argonne, IL 60439, USA
| | - S Wilbur
- University of California, Davis, Davis, CA 95616, USA
| | - H H Williams
- University of Pennsylvania, Philadelphia, PA 19104, USA
| | - J S Wilson
- University of Michigan, Ann Arbor, MI 48109, USA
| | - P Wilson
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - B L Winer
- The Ohio State University, Columbus, OH 43210, USA
| | - P Wittich
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - S Wolbers
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | | | - T Wright
- University of Michigan, Ann Arbor, MI 48109, USA
| | - X Wu
- University of Geneva, CH-1211 Geneva 4, Switzerland
| | - Z Wu
- Baylor University, Waco, TX 76798, USA
| | - K Yamamoto
- Osaka City University, Osaka 558-8585, Japan
| | - D Yamato
- Osaka City University, Osaka 558-8585, Japan
| | - T Yang
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - U K Yang
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - Y C Yang
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - W-M Yao
- Ernest Orlando Lawrence Berkeley National Laboratory, Berkeley, CA 94720, USA
| | - G P Yeh
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - K Yi
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - J Yoh
- Fermi National Accelerator Laboratory, Batavia, IL 60510, USA
| | - K Yorita
- Waseda University, Tokyo 169, Japan
| | - T Yoshida
- Osaka City University, Osaka 558-8585, Japan
| | - G B Yu
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - I Yu
- Center for High Energy Physics, Kyungpook National University, Daegu 702-701, Korea.,Seoul National University, Seoul 151-742, Korea.,Sungkyunkwan University, Suwon 440-746, Korea.,Korea Institute of Science and Technology Information, Daejeon 305-806, Korea.,Chonnam National University, Gwangju 500-757, Korea.,Chonbuk National University, Jeonju 561-756, Korea.,Ewha Womans University, Seoul 120-750, Korea
| | - A M Zanetti
- Istituto Nazionale di Fisica Nucleare Trieste, I-34127 Trieste, Italy
| | - Y Zeng
- Duke University, Durham, NC 27708, USA
| | - C Zhou
- Duke University, Durham, NC 27708, USA
| | - S Zucchelli
- Istituto Nazionale di Fisica Nucleare Bologna, I-40127 Bologna, Italy.,University of Bologna, I-40127 Bologna, Italy
| |
Collapse
|
28
|
Liu L, Bai F, Song H, Xiao R, Wang Y, Yang H, Ren X, Li S, Gao L, Ma C, Yang X, Liang X. Corrigendum to “Upregulation of TIPE1 in tubular epithelial cell aggravates diabetic nephropathy by disrupting PHB2 mediated mitophagy” [Redox Biol. 50 (2022) 2213–2317/102260]. Redox Biol 2022; 52:102302. [PMID: 35365434 PMCID: PMC9108084 DOI: 10.1016/j.redox.2022.102302] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/05/2022] Open
|
29
|
Shenker R, Price J, Jacobs C, Niedzwiecki D, Oyekunle T, Song H, Palta M, Czito B, Kirkpatrick J, Mowery Y, Jr MM, Salama J. Oligometastases Treated With an Elective Simultaneous Integrated Boost Have Reduced Marginal Recurrence Rates. Int J Radiat Oncol Biol Phys 2021. [DOI: 10.1016/j.ijrobp.2021.07.1331] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|
30
|
Song H. Current Status and Prospects of Camrelizumab, A Humanized Antibody Against Programmed Cell Death Receptor 1. Recent Pat Anticancer Drug Discov 2021. [DOI: 10.2174/22123970mte0emdy90] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/22/2022]
|
31
|
Gao JD, Song H, Fu P, Guo YX, Zhang HY, Qiu M. Effects of etomidate on cell apoptosis during myocardial ischemia-reperfusion. J BIOL REG HOMEOS AG 2021; 35:10. [PMID: 34350750 DOI: 10.23812/21-si1-10] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- J D Gao
- Department of Pain, Yantaishan Hospital, Yantai, China
| | - H Song
- Emergency Department, Jinan Zhangqiu District Hospital of TCM, Jinan, China
| | - P Fu
- Department of Anesthesiology, Qingdao Fuwai Cardiovascular Hospital, Qingdao, China
| | - Y X Guo
- Department of Respiratory, Jinan Zhangqiu District People's Hospital, Jinan, China
| | - H Y Zhang
- Department of Pediatrics, Jinan Zhangqiu District People's Hospital, Jinan, China
| | - M Qiu
- Department of Anesthesiology, Jinan Municipal Hospital of Traditional Chinese Medicine, Jinan, China
| |
Collapse
|
32
|
Song H, Qu HC, Liu S, Shen XX. MiR-27 inhibits cell migration and invasion by targeting CREB1 to influence MAPK/ERK signaling pathway in breast cancer. J BIOL REG HOMEOS AG 2021; 35:11. [PMID: 34350751 DOI: 10.23812/21-si1-11] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/11/2022]
Affiliation(s)
- H Song
- Department of Breast surgery, Zhangqiu Maternity and Child Care Hospital, Jinan, China
| | - H C Qu
- Outpatient Operating Room, Zhangqiu Maternity and Child Care Hospital, Jinan, China
| | - S Liu
- Department of Emergency, Zhangqiu Maternity and Child Care Hospital, Jinan, China
| | - X X Shen
- Department of Nursing, Zhangqiu Maternity and Child Care Hospital, Jinan, China
| |
Collapse
|
33
|
Li XF, Shi ZD, Song H, Wang YL, Li QC, Diao XH, Pang YW, Zhou SH, Liu HY. Protective effects of L-carnitine on reproductive capacity in rats with diabetes. J Physiol Pharmacol 2021; 72. [PMID: 34272348 DOI: 10.26402/jpp.2021.1.12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Received: 01/26/2021] [Accepted: 02/26/2021] [Indexed: 11/03/2022]
Abstract
To explore the protective effects of L-carnitine on erectile function and reproductive function in rats with diabetes. A total of 60 male diabetes mellitus induced-erectile dysfunction (DMED) rats were randomly divided into three groups, 20 rats in each group. The blank group was fed normally, the control group was fed with 0.9% sodium chloride solution 5 ml/kg/day, and the experimental group was given L-carnitine 300 mg/kg/day. After six weeks, the Corpus cavernosum penis pressure (ICP) and mean arterial pressure (MAP) were measured. The sperm of epididymis were taken to detect the parameters of sperm. After six weeks of treatment, ICP and MAP in the experimental group were significantly higher than those in the control group and blank group (p < 0.05), and sperm density and PR in the experimental group were significantly higher than those in the control group and the blank group (p < 0.05). Superoxide dismutase (SOD) in the experimental group was significantly higher than that in the control group and blank group (p < 0.05). Malondialdehyde (MDA) in the experimental group was significantly lower than that in the control group and blank group (p < 0.05). The follicle-stimulating hormone (FSH), luteinizing hormone (LH), and testosterone in the experimental group were significantly higher than those in the control group and blank group (p < 0.05). We conclude that L-carnitine can significantly improve erectile function and reproductive function in rats with diabetes and it has great potential in the treatment of systemic organ damage in DMED rats.
Collapse
Affiliation(s)
- X-F Li
- Department of Reproductive Medicine, Binzhou Medical University Hospital, Binzhou, China
| | - Z-D Shi
- Department of Urology, The Affiliated School of Clinical Medicine of Xuzhou Medical College, Xuzhou Central Hospital, Xuzhou, China
| | - H Song
- Department of Infectious Disease, The Fourth People Hospital of ZiBo, ZiBo, China
| | - Y-L Wang
- Department of Reproductive Medicine, Binzhou Medical University Hospital, Binzhou, China
| | - Q-C Li
- Department of Reproductive Medicine, Binzhou Medical University Hospital, Binzhou, China
| | - X-H Diao
- Department of Reproductive Medicine, Binzhou Medical University Hospital, Binzhou, China
| | - Y-W Pang
- Department of Reproductive Medicine, Binzhou Medical University Hospital, Binzhou, China
| | - S-H Zhou
- Department of Reproductive Medicine, Binzhou Medical University Hospital, Binzhou, China
| | - H-Y Liu
- Department of Gastroenterology, Binzhou Medical University Hospital, Binzhou, China.
| |
Collapse
|
34
|
Song H, Wang X, Li JC, Lv YH. MiR-655-3p inhibits growth and invasiveness of trophoblasts via targeting PBX3 and thus deteriorates preeclampsia. Eur Rev Med Pharmacol Sci 2021; 24:10346-10351. [PMID: 33155190 DOI: 10.26355/eurrev_202010_23383] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE The purpose of this study was to elucidate the regulatory effects of microRNA-655-3p (miR-655-3p) on growth and invasiveness of trophoblasts to influence the development of preeclampsia (PE). PATIENTS AND METHODS Relative levels of miR-655-3p and PBX3 in 24 PE pregnant women and 24 healthy ones were examined. Then, the regulatory effects of miR-655-3p and PBX3 on viability and invasiveness in HTR-8/SVneo cells were assessed by Cell Counting Kit-8 (CCK-8) and transwell assay, respectively. Next, the expression levels of apoptosis-associated genes were determined. Finally, the interaction between miR-655-3p and PBX3 was tested by Dual-Luciferase reporter assay. RESULTS MiR-655-3p was upregulated in placental tissues of PE pregnant women than those of healthy ones. The overexpression of miR-655-3p suppressed viability and invasiveness, and induced apoptosis in HTR-8/SVneo cells. Besides, PBX3 was the target gene binding to miR-655-3p, and more importantly, the overexpression of PBX3 partially reversed the regulatory effects of miR-655-3p on viability and invasiveness in HTR-8/SVneo cells. CONCLUSIONS MiR-655-3p is involved in the development of PE by regulating biological features of trophoblasts by targeting PBX3.
Collapse
Affiliation(s)
- H Song
- Department of Obstetrics, Binzhou Central Hospital, Binzhou, China.
| | | | | | | |
Collapse
|
35
|
Rrapi R, Chand S, Lo JA, Gabel CK, Song S, Holcomb Z, Iriarte C, Moore K, Shi CR, Song H, Xia FD, Yanes D, Gandhi R, Triant VA, Kroshinsky D. The significance of exanthems in COVID-19 patients hospitalized at a tertiary care centre. J Eur Acad Dermatol Venereol 2021; 35:e640-e642. [PMID: 34146347 PMCID: PMC8447347 DOI: 10.1111/jdv.17459] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
Affiliation(s)
- R Rrapi
- Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA
| | - S Chand
- Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA
| | - J A Lo
- Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA.,Harvard Combined Dermatology Residency, Harvard Medical School, Boston, MA, USA
| | - C K Gabel
- Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA
| | - S Song
- Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA
| | - Z Holcomb
- Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA.,Harvard Combined Dermatology Residency, Harvard Medical School, Boston, MA, USA
| | - C Iriarte
- Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA.,Harvard Combined Dermatology Residency, Harvard Medical School, Boston, MA, USA
| | - K Moore
- Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA.,Harvard Combined Dermatology Residency, Harvard Medical School, Boston, MA, USA
| | - C R Shi
- Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA.,Harvard Combined Dermatology Residency, Harvard Medical School, Boston, MA, USA
| | - H Song
- Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA.,Harvard Combined Dermatology Residency, Harvard Medical School, Boston, MA, USA
| | - F D Xia
- Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA.,Harvard Combined Dermatology Residency, Harvard Medical School, Boston, MA, USA
| | - D Yanes
- Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA.,Harvard Combined Dermatology Residency, Harvard Medical School, Boston, MA, USA
| | - R Gandhi
- Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA
| | - V A Triant
- Division of Infectious Diseases, Massachusetts General Hospital, Boston, MA, USA.,Division of General Internal Medicine, Massachusetts General Hospital, Boston, MA, USA
| | - D Kroshinsky
- Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA
| |
Collapse
|
36
|
Wang YJ, Zhang HL, Song H, Zhang F, Xi YF. [Research progress on prognostic factors of extranodal NK/T-cell lymphoma]. Zhonghua Bing Li Xue Za Zhi 2021; 50:691-694. [PMID: 34078068 DOI: 10.3760/cma.j.cn112151-20201224-00958] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Affiliation(s)
- Y J Wang
- School of Basic Medicine, Shanxi Medical University, Taiyuan 030000, China
| | - H L Zhang
- Department of Pathology, Second Medical College of Shanxi Medical University, Taiyuan 030000, China
| | - H Song
- School of Basic Medicine, Shanxi Medical University, Taiyuan 030000, China
| | - F Zhang
- School of Basic Medicine, Shanxi Medical University, Taiyuan 030000, China
| | - Y F Xi
- Department of Pathology, Shanxi Cancer Hospital, Taiyuan 030000, China
| |
Collapse
|
37
|
Linggonegoro DW, Song H, Jones KM, Lee PY, Schmidt B, Vleugels RA, Huang JT. Familial chilblain lupus in a child with heterozygous mutation in SAMHD1 and normal interferon signature. Br J Dermatol 2021; 185:650-652. [PMID: 33887057 DOI: 10.1111/bjd.20400] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/17/2020] [Revised: 02/10/2021] [Accepted: 04/16/2021] [Indexed: 12/26/2022]
Affiliation(s)
| | - H Song
- Harvard Medical School, Boston, MA, USA.,Harvard Combined Dermatology Residency Program, Boston, MA, USA
| | - K M Jones
- Department of Dermatology, Boston Children's Hospital, Boston, MA, USA
| | - P Y Lee
- Division of Immunology, Boston Children's Hospital, Boston, MA, USA
| | - B Schmidt
- Department of Pathology, Boston Children's Hospital, Boston, MA, USA
| | - R A Vleugels
- Department of Dermatology, Brigham and Women's Hospital, Boston, MA, USA
| | - J T Huang
- Department of Dermatology, Boston Children's Hospital, Boston, MA, USA
| |
Collapse
|
38
|
Ortiz C, Bitar R, Garza L, Parker M, Hyman C, Suri R, Song H, Walker J, Lopera J. Abstract No. 171 Validating an ex-vivo bovine kidney pulsatile perfusion model with micro-CT evaluation of distal angioembolization. J Vasc Interv Radiol 2021. [DOI: 10.1016/j.jvir.2021.03.177] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/21/2022] Open
|
39
|
Bitar R, Garza L, Parker M, Ortiz C, Suri R, Lopera J, Song H, Walker J. Abstract No. 130 Evaluation of an experimental radiopaque microsphere in an ex vivo perfusion model. J Vasc Interv Radiol 2021. [DOI: 10.1016/j.jvir.2021.03.136] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
40
|
Song G, Ip K, Shan A, Banov D, Song H, Bassani A, Carvalho M, Day A. 476 Evaluation of the in vitro percutaneous absorption of progesterone, testosterone, estriol and estradiol topical compounded formulations. J Invest Dermatol 2021. [DOI: 10.1016/j.jid.2021.02.500] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]
|
41
|
Yao L, Yang L, Song H, Liu TG, Yan H. Silencing of lncRNA XIST suppresses proliferation and autophagy and enhances vincristine sensitivity in retinoblastoma cells by sponging miR-204-5p. Eur Rev Med Pharmacol Sci 2021; 24:3526-3537. [PMID: 32329826 DOI: 10.26355/eurrev_202004_20812] [Citation(s) in RCA: 9] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE Retinoblastoma (RB) is the most prevalent intraocular malignancy in childhood. Long non-coding RNAs (lncRNAs) have been found as critical oncogenic drivers and tumor suppressor in RB. The aim of the present work was to investigate the impact and mechanism of XIST on RB cell autophagy and vincristine (VCR) sensitivity. MATERIALS AND METHODS The levels of XIST and miR-204-5p were assessed by quantitative Real Time-Polymerase Chain Reaction (qRT-PCR). Western blot analysis was used for the determination of related protein levels. Cell proliferation and IC50 value of VCR were detected using the 3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium (MTS) assay. Flow cytometry was performed to evaluate cell apoptosis. The activities of caspase-3 and caspase-9 were identified using a corresponding assay kit. The direct interaction between XIST and miR-204-5p was confirmed using Dual-Luciferase reporter assay. Xenograft model was established to observe the effect of XIST on RB in vivo. RESULTS Our data indicated that XIST was highly expressed in RB tissues and cell lines. XIST knockdown weakened the proliferation and autophagy and enhanced VCR sensitivity in RB cells. XIST acted as a molecular sponge of miR-204-5p. Moreover, the regulatory effects of XIST silencing on RB cell proliferation, autophagy and VCR sensitivity were mediated by miR-204-5p. Additionally, XIST silencing weakened tumor growth and enhanced VCR sensitivity in vivo through up-regulating miR-204-5p. CONCLUSIONS Our current study suggested that XIST silencing suppressed RB progression and promoted VCR sensitivity in vitro and in vivo at least partially by acting as a miR-204-5p sponge, highlighting a powerful therapeutic strategy for RB treatment.
Collapse
Affiliation(s)
- L Yao
- Department of Ophthalmology, Tianjin Medical University General Hospital, Tianjin, China.
| | | | | | | | | |
Collapse
|
42
|
Xu XZ, Song H, Zhao Y, Zhang L. MiR-654-5p regulated cell progression and tumor growth through targeting SIRT6 in osteosarcoma. Eur Rev Med Pharmacol Sci 2021; 24:3517-3525. [PMID: 32329825 DOI: 10.26355/eurrev_202004_20811] [Citation(s) in RCA: 6] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE MiRNAs are important regulators in cell progression, tumor formation, and development. The poor prognosis and high incidence of osteosarcoma are difficult to treat. Therefore, studying the mechanism of OS progression is conducive to the diagnosis and treatment of OS. However, the role of miRNA in OS progression has not been fully explored. MATERIALS AND METHODS The expression of miR-654-5p and SIRT6 was detected using qRT-PCR. Western blot was applied to measure the protein expression of SIRT6. Transfected cells proliferation was measured using MTT assay. Transwell was performed to assess cell migrated and invasive capacity. Animals experiment was used to verify the regulatory mechanism of miR-654-5p in OS. RESULTS In this study, we found that miR-654-3p was downregulated while SIRT6 expression was upregulated in OS tissues and cells. Meanwhile, the overexpression of miR-654-5p suppressed cell proliferation, invasion, and migration in OS cells. Otherwise, Luciferase reporter assay determined that SIRT6 was a target gene of miR-654-5p. Notably, the promotion effect of anti-miR-654-5p on cell proliferation, migration, and invasion was reversed by inhibition of SIRT6 in OS. Moreover, the promotion of miR-654-5p inhibited OS tumor growth in vivo. CONCLUSIONS MiR-654-5p regulated cell progression and tumor growth by targeting SIRT6 in OS, providing a new therapeutic target for OS.
Collapse
Affiliation(s)
- X-Z Xu
- Department of Emergency Surgery, Yantai Affiliated Hospital of Binzhou Medical University, Yantai City, Shandong Province, China.
| | | | | | | |
Collapse
|
43
|
Chang YZ, Shi WH, Han GY, Song H, Hou WJ. Fabrication on the Flexible Supercapacitor Based on the Polypyrrole Deposited on Polyethylene/Polypropylene Non-Woven Film. RUSS J ELECTROCHEM+ 2021. [DOI: 10.1134/s1023193520060038] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
|
44
|
Yi J, Yang MM, Luo XD, Rosenkranz A, Wang B, Song H, Jiang N. Unprecedented tribological performance of binary Sb/Ag-doped MoS2 coatings fabricated with chemical vapor deposition. Appl Nanosci 2021. [DOI: 10.1007/s13204-020-01638-x] [Citation(s) in RCA: 5] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 10/22/2022]
|
45
|
Xiao F, Shi X, Huang P, Zeng X, Wang L, Zeng J, Liu C, Yan B, Song H, Xu Y, Han L, Zhao Q, Lin M, Li X. Dose-response relationship between serum fibroblast growth factor 21 and liver fat content in non-alcoholic fatty liver disease. Diabetes Metab 2020; 47:101221. [PMID: 33373666 DOI: 10.1016/j.diabet.2020.101221] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/18/2020] [Revised: 12/03/2020] [Accepted: 12/06/2020] [Indexed: 11/24/2022]
Abstract
BACKGROUND & AIM Although serum fibroblast growth factor 21 (FGF21) levels are associated with liver fat content in non-alcoholic liver fat disease (NAFLD), the precise nature of the association remains undetermined. Therefore, this study aimed to explore the potential dose-response relationship between FGF21 and liver fat content in NAFLD. METHODS For this exploratory study from a randomized trial, 220 NAFLD patients with central obesity were recruited via community-based screening and randomly assigned to either control, moderate or vigorous-moderate exercise groups for 12 months. After this exercise intervention, patients were followed-up for a further 12 months. Serum FGF21 levels were measured by ELISA. Intrahepatic triglyceride (IHTG) content was determined by proton magnetic resonance spectroscopy. RESULTS Of the 220 patients, 149 (67.7%) were female; mean age was 53.9 ± 7.1 years and mean BMI was 28.0 ± 2.9 kg/m2 for all patients. Baseline IHGT increased gradually (P = 0.029 for trend) according to baseline serum FGF21 quartiles 1, 2, 3 and 4 (212.3, 358.9, 538.7 and 793.5 pg/mL, respectively). On grouping the distribution of serum FGF21 level changes into quartiles at month 12, the relative IHTG loss increased as serum FGF21 levels were reduced (P = 0.004 for trend). A similar trend was observed at month 24 (P = 0.006 for trend). Multivariate linear regression analysis revealed that changes in serum FGF21 levels were independently associated with changes in IHTG at both month 12 [β (SE), 0.136 (0.118); P = 0.048] and month 24 [β (SE), 0.152 (0.139); P = 0.041]. Using restricted cubic spline regression, changes in serum FGF21 were strongly and positively associated with their corresponding relative IHTG loss at both month 12 and follow-up (Poverall = 0.017, Pnon-linear = 0.044 and Poverall = 0.020, Pnon-linear = 0.361, respectively, for dose-response). CONCLUSION Serum FGF21 is strongly associated with liver fat content in a dose-response manner in centrally obese NAFLD patients. These findings support the use of serum FGF21 as a biomarker of liver fat content in NAFLD.
Collapse
Affiliation(s)
- F Xiao
- Department of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, Xiamen, China; Xiamen Clinical Medical Centre for Endocrine and Metabolic Diseases, Xiamen, China; Fujian Province Key Laboratory of Diabetes Translational Medicine, Xiamen, China; School of Clinical Medicine, Fujian Medical University, Fuzhou, China
| | - X Shi
- Department of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, Xiamen, China; Xiamen Clinical Medical Centre for Endocrine and Metabolic Diseases, Xiamen, China; Fujian Province Key Laboratory of Diabetes Translational Medicine, Xiamen, China; School of Clinical Medicine, Fujian Medical University, Fuzhou, China
| | - P Huang
- Department of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, Xiamen, China; Xiamen Clinical Medical Centre for Endocrine and Metabolic Diseases, Xiamen, China; Fujian Province Key Laboratory of Diabetes Translational Medicine, Xiamen, China; School of Clinical Medicine, Fujian Medical University, Fuzhou, China
| | - X Zeng
- Fujian Province Key Laboratory of Diabetes Translational Medicine, Xiamen, China; Xiamen Diabetes Institute, Xiamen, China
| | - L Wang
- Department of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, Xiamen, China; Xiamen Clinical Medical Centre for Endocrine and Metabolic Diseases, Xiamen, China; Fujian Province Key Laboratory of Diabetes Translational Medicine, Xiamen, China
| | - J Zeng
- Department of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, Xiamen, China; Xiamen Clinical Medical Centre for Endocrine and Metabolic Diseases, Xiamen, China; Fujian Province Key Laboratory of Diabetes Translational Medicine, Xiamen, China
| | - C Liu
- Department of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, Xiamen, China; Xiamen Clinical Medical Centre for Endocrine and Metabolic Diseases, Xiamen, China; Fujian Province Key Laboratory of Diabetes Translational Medicine, Xiamen, China
| | - B Yan
- Department of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, Xiamen, China; Xiamen Clinical Medical Centre for Endocrine and Metabolic Diseases, Xiamen, China; Xiamen Diabetes Institute, Xiamen, China
| | - H Song
- Department of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, Xiamen, China; Xiamen Clinical Medical Centre for Endocrine and Metabolic Diseases, Xiamen, China; Fujian Province Key Laboratory of Diabetes Translational Medicine, Xiamen, China
| | - Y Xu
- School of Clinical Medicine, Fujian Medical University, Fuzhou, China
| | - L Han
- School of Clinical Medicine, Fujian Medical University, Fuzhou, China
| | - Q Zhao
- School of Medicine, Xiamen University, Xiamen, China
| | - M Lin
- Department of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, Xiamen, China; Xiamen Clinical Medical Centre for Endocrine and Metabolic Diseases, Xiamen, China; Fujian Province Key Laboratory of Diabetes Translational Medicine, Xiamen, China; Xiamen Diabetes Institute, Xiamen, China; School of Clinical Medicine, Fujian Medical University, Fuzhou, China.
| | - X Li
- Department of Endocrinology and Diabetes, The First Affiliated Hospital of Xiamen University, Xiamen, China; Xiamen Clinical Medical Centre for Endocrine and Metabolic Diseases, Xiamen, China; Fujian Province Key Laboratory of Diabetes Translational Medicine, Xiamen, China; Xiamen Diabetes Institute, Xiamen, China; School of Clinical Medicine, Fujian Medical University, Fuzhou, China.
| |
Collapse
|
46
|
Wei F, Zheng GQ, Song H, Liang YF, Yin WJ, Sun NN, Yang YX. [Prognostic value of new TNM staging and serum CA125 in malignant peritoneal mesothelioma]. Zhonghua Lao Dong Wei Sheng Zhi Ye Bing Za Zhi 2020; 38:321-326. [PMID: 32536066 DOI: 10.3760/cma.j.cn121094-20190821-00348] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To explore the relationship between the new Tumor-Node-Metastasis (TNM) staging system and the serum CA125 level with the prognosis of malignant peritoneal mesothelioma (MPeM) . Methods: The clinical data of 74 patients with MPeM diagnosed by pathology and immunohistochemistry were collected from January 2005 to June 2016 in Cangzhou Central Hospital. According to the results of CT-peritoneal carcinoma index (PCI) , the tumor load was divided into T1 (PCI 1-10) , T2 (PCI 11-20) , T3 (PCI 21-30) and T4 (PCI 31-39) , combined with lymph node metastasis and extraperitoneal metastasis, a new TNM staging system was established. And serum CA125 level was measured in the same time. The median survival time of patients with MPeM, the effect of the new TNM staging system, and serum CA125 levels on their prognosis were retrospectively analyzed. Results: Among the 74 patients with MPeM, 25 (33.8%) cases were males and 49 (66.2%) cases were females. There were 8 cases with systemic chemotherapy, 8 cases with heated intraperitoneal chemotherapy, and 1 case with combination chemotherapy. 10 cases were T1, 22 cases were T2, 27 cases were T3, 15 cases were T4, 12 cases had lymph node metastasis and 10 cases had distant metastasis. The median survival time of T1, T2, T3 and T4 were 12, 10, 6 and 3 months respectively. There were 38 (77.6%) cases with high serum CA125 in all 49 cases who have been tested for CA125. The median survival time of positive group and negative group were 6 months and 11 months respectively. 68 (91.9%) patients had died by the end of collecting data. The median survival time was 8 months. Univariate analysis showed that there were significant differences in survival time between patients with different CT-PCI stages, serum CA125 levels, and with or without lymph node and extraperitoneal metastasis (P<0.05) . Multivariate analysis showed that CT-PCI was independent risk factors for the prognosis of MPeM (HR=2.203, 95%CI: 1.475-3.289) . Conclusion: The new TNM staging system and serum CA125 are important for the prognosis of patients with MPeM. Early detection, early diagnosis and comprehensive treatment can improve the survival time of patients with MPeM.
Collapse
Affiliation(s)
- F Wei
- Digestive Department, Cangzhou Central Hospital, Cangzhou 061001, China
| | - G Q Zheng
- Digestive Department, Cangzhou Central Hospital, Cangzhou 061001, China
| | - H Song
- Digestive Department, Cangzhou Central Hospital, Cangzhou 061001, China
| | - Y F Liang
- Digestive Department, Cangzhou Central Hospital, Cangzhou 061001, China
| | - W J Yin
- Digestive Department, Cangzhou Central Hospital, Cangzhou 061001, China
| | - N N Sun
- Digestive Department, Cangzhou Central Hospital, Cangzhou 061001, China
| | - Y X Yang
- Digestive Department, Cangzhou Central Hospital, Cangzhou 061001, China
| |
Collapse
|
47
|
Ge H, Luo H, Song H, Mao R, Laster K, Jia X. Serum Proteomic Profiling Reveals that Pretreatment Complement C3a and BIP Levels are Predictive of Esophageal Squamous Cell Carcinoma Patient Response to Definitive Chemoradiotherapy. Int J Radiat Oncol Biol Phys 2020. [DOI: 10.1016/j.ijrobp.2020.07.1720] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
|
48
|
Thompson LL, Chang MS, McCormack L, Polyakov N, Yoon J, Song H, Huang JT, Chen ST. Patterns of cutaneous immune-related adverse events in adults and children with advanced sarcoma: a retrospective cohort study. Br J Dermatol 2020; 184:363-365. [PMID: 32894776 DOI: 10.1111/bjd.19540] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/22/2020] [Revised: 08/30/2020] [Accepted: 08/31/2020] [Indexed: 11/27/2022]
Affiliation(s)
- L L Thompson
- Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA.,Harvard Medical School, Boston, MA, USA
| | - M S Chang
- Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA.,Harvard Medical School, Boston, MA, USA
| | - L McCormack
- Department of Dermatology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.,University of Massachusetts Medical School, Worcester, MA, USA
| | - N Polyakov
- Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA.,Harvard Medical School, Boston, MA, USA
| | - J Yoon
- Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA.,Harvard Medical School, Boston, MA, USA
| | - H Song
- Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA.,Department of Dermatology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.,Harvard Combined Dermatology Residency Program, Harvard Medical School, Boston, MA, USA
| | - J T Huang
- Department of Dermatology, Boston Children's Hospital and Harvard Medical School, Boston, MA, USA.,Department of Dermatology, Harvard Medical School, Boston, MA, USA
| | - S T Chen
- Department of Dermatology, Massachusetts General Hospital, Boston, MA, USA.,Department of Dermatology, Harvard Medical School, Boston, MA, USA
| |
Collapse
|
49
|
Liao C, Shen DY, Xu XJ, Xu WQ, Zhang JY, Song H, Yang SL, Zhao FY, Shen HP, Tang YM. [Long-term outcome of childhood T-cell acute lymphoblastic leukemia treated with modified national protocol of childhood leukemia in China-acute lymphoblastic leukemia 2008]. Zhonghua Er Ke Za Zhi 2020; 58:758-763. [PMID: 32872717 DOI: 10.3760/cma.j.cn12140-20200116-00035] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 11/05/2022]
Abstract
Objective: To analyse the long-term efficacy in childhood T-cell acute lymphoblastic leukemia (T-ALL) cases enrolled in the national protocol of childhood leukemia in China-acute lymphoblastic leukemia (NPCLC-ALL) 2008. Methods: Clinical data of 96 patients diagnosed as T-ALL and treated with NPCLC-ALL2008 protocol between January 2009 and December 2017 in the Department of Hematology-Oncology, the Children's Hospital, Zhejiang University School of Medicine were analyzed retrospectively. Predictive value of minimal residual disease (MRD) monitored by flow cytometry was analyzed. Kaplan-Meier method was used for long-term survival analysis. Results: A total of 96 evaluable patients with newly diagnosed T-ALL were analysed, including 72 males and 24 females. The age was 9.5 (ranged from 1.0 to 16.0) years. The follow-up time was 5.7 (ranged from 1.0 to 9.7) years. Among 96 patients, 92 (96%) achieved complete remission. The 5-year event free survival (EFS) and overall survival (OS) rates were (61±6) % and (70±5) %, respectively. Relapse occurred in 18 cases and the 5-year cumulative incidence of relapse was (27±6) %. Twenty-four patients died. The 5-year OS rates of patients with MRD>5% on day 15 of induction therapy was significantly worse than those with MRD≤5% ((60±12) % vs. (72±6) %, χ(2)=3.904, P=0.048) . The 5-year EFS and OS rates were obviously lower in patients with MRD>10% before the consolidation therapy ((50±35) %). The 5-year OS rates of patients with relapsed disease was significantly worse than those without ((26±13) % vs. (81±5) %, χ(2)=18.411, P<0.01). The earlier the relapse, the worse the prognosis. The 5-year OS rates for patients relapsed within 6 months, within 3 years and more than 3 years, were (25±22) %, (30±14) % and (50±35) % respectively (χ(2)=13.207, P<0.01). Conclusions: NPCLC-ALL2008 protocol is effective for childhood T-ALL. The MRD guided accurate risk stratification and individualized treatment can reduce the relapse and improve the survival rate of pediatric T-ALL.
Collapse
Affiliation(s)
- C Liao
- Department of Hematology-Oncology, the Children's Hospital, Zhejiang University School of Medicine, Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, National Clinical Research Center for Child Health, Hangzhou 310003, China
| | - D Y Shen
- Department of Hematology-Oncology, the Children's Hospital, Zhejiang University School of Medicine, Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, National Clinical Research Center for Child Health, Hangzhou 310003, China
| | - X J Xu
- Department of Hematology-Oncology, the Children's Hospital, Zhejiang University School of Medicine, Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, National Clinical Research Center for Child Health, Hangzhou 310003, China
| | - W Q Xu
- Department of Hematology-Oncology, the Children's Hospital, Zhejiang University School of Medicine, Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, National Clinical Research Center for Child Health, Hangzhou 310003, China
| | - J Y Zhang
- Department of Hematology-Oncology, the Children's Hospital, Zhejiang University School of Medicine, Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, National Clinical Research Center for Child Health, Hangzhou 310003, China
| | - H Song
- Department of Hematology-Oncology, the Children's Hospital, Zhejiang University School of Medicine, Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, National Clinical Research Center for Child Health, Hangzhou 310003, China
| | - S L Yang
- Department of Hematology-Oncology, the Children's Hospital, Zhejiang University School of Medicine, Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, National Clinical Research Center for Child Health, Hangzhou 310003, China
| | - F Y Zhao
- Department of Hematology-Oncology, the Children's Hospital, Zhejiang University School of Medicine, Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, National Clinical Research Center for Child Health, Hangzhou 310003, China
| | - H P Shen
- Department of Hematology-Oncology, the Children's Hospital, Zhejiang University School of Medicine, Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, National Clinical Research Center for Child Health, Hangzhou 310003, China
| | - Y M Tang
- Department of Hematology-Oncology, the Children's Hospital, Zhejiang University School of Medicine, Pediatric Leukemia Diagnostic and Therapeutic Technology Research Center of Zhejiang Province, National Clinical Research Center for Child Health, Hangzhou 310003, China
| |
Collapse
|
50
|
Millstein J, Budden T, Goode EL, Anglesio MS, Talhouk A, Intermaggio MP, Leong HS, Chen S, Elatre W, Gilks B, Nazeran T, Volchek M, Bentley RC, Wang C, Chiu DS, Kommoss S, Leung SCY, Senz J, Lum A, Chow V, Sudderuddin H, Mackenzie R, George J, Fereday S, Hendley J, Traficante N, Steed H, Koziak JM, Köbel M, McNeish IA, Goranova T, Ennis D, Macintyre G, Silva De Silva D, Ramón Y Cajal T, García-Donas J, Hernando Polo S, Rodriguez GC, Cushing-Haugen KL, Harris HR, Greene CS, Zelaya RA, Behrens S, Fortner RT, Sinn P, Herpel E, Lester J, Lubiński J, Oszurek O, Tołoczko A, Cybulski C, Menkiszak J, Pearce CL, Pike MC, Tseng C, Alsop J, Rhenius V, Song H, Jimenez-Linan M, Piskorz AM, Gentry-Maharaj A, Karpinskyj C, Widschwendter M, Singh N, Kennedy CJ, Sharma R, Harnett PR, Gao B, Johnatty SE, Sayer R, Boros J, Winham SJ, Keeney GL, Kaufmann SH, Larson MC, Luk H, Hernandez BY, Thompson PJ, Wilkens LR, Carney ME, Trabert B, Lissowska J, Brinton L, Sherman ME, Bodelon C, Hinsley S, Lewsley LA, Glasspool R, Banerjee SN, Stronach EA, Haluska P, Ray-Coquard I, Mahner S, Winterhoff B, Slamon D, Levine DA, Kelemen LE, Benitez J, Chang-Claude J, Gronwald J, Wu AH, Menon U, Goodman MT, Schildkraut JM, Wentzensen N, Brown R, Berchuck A, Chenevix-Trench G, deFazio A, Gayther SA, García MJ, Henderson MJ, Rossing MA, Beeghly-Fadiel A, Fasching PA, Orsulic S, Karlan BY, Konecny GE, Huntsman DG, Bowtell DD, Brenton JD, Doherty JA, Pharoah PDP, Ramus SJ. Prognostic gene expression signature for high-grade serous ovarian cancer. Ann Oncol 2020; 31:1240-1250. [PMID: 32473302 PMCID: PMC7484370 DOI: 10.1016/j.annonc.2020.05.019] [Citation(s) in RCA: 72] [Impact Index Per Article: 18.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/04/2020] [Revised: 05/06/2020] [Accepted: 05/06/2020] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND Median overall survival (OS) for women with high-grade serous ovarian cancer (HGSOC) is ∼4 years, yet survival varies widely between patients. There are no well-established, gene expression signatures associated with prognosis. The aim of this study was to develop a robust prognostic signature for OS in patients with HGSOC. PATIENTS AND METHODS Expression of 513 genes, selected from a meta-analysis of 1455 tumours and other candidates, was measured using NanoString technology from formalin-fixed paraffin-embedded tumour tissue collected from 3769 women with HGSOC from multiple studies. Elastic net regularization for survival analysis was applied to develop a prognostic model for 5-year OS, trained on 2702 tumours from 15 studies and evaluated on an independent set of 1067 tumours from six studies. RESULTS Expression levels of 276 genes were associated with OS (false discovery rate < 0.05) in covariate-adjusted single-gene analyses. The top five genes were TAP1, ZFHX4, CXCL9, FBN1 and PTGER3 (P < 0.001). The best performing prognostic signature included 101 genes enriched in pathways with treatment implications. Each gain of one standard deviation in the gene expression score conferred a greater than twofold increase in risk of death [hazard ratio (HR) 2.35, 95% confidence interval (CI) 2.02-2.71; P < 0.001]. Median survival [HR (95% CI)] by gene expression score quintile was 9.5 (8.3 to -), 5.4 (4.6-7.0), 3.8 (3.3-4.6), 3.2 (2.9-3.7) and 2.3 (2.1-2.6) years. CONCLUSION The OTTA-SPOT (Ovarian Tumor Tissue Analysis consortium - Stratified Prognosis of Ovarian Tumours) gene expression signature may improve risk stratification in clinical trials by identifying patients who are least likely to achieve 5-year survival. The identified novel genes associated with the outcome may also yield opportunities for the development of targeted therapeutic approaches.
Collapse
Affiliation(s)
- J Millstein
- Division of Biostatistics, Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, USA
| | - T Budden
- School of Women's and Children's Health, Faculty of Medicine, University of NSW Sydney, Sydney, Australia; CRUK Manchester Institute, The University of Manchester, Manchester, UK
| | - E L Goode
- Department of Health Science Research, Division of Epidemiology, Mayo Clinic, Rochester, USA
| | - M S Anglesio
- British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada
| | - A Talhouk
- British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada
| | - M P Intermaggio
- School of Women's and Children's Health, Faculty of Medicine, University of NSW Sydney, Sydney, Australia
| | - H S Leong
- Peter MacCallum Cancer Center, Melbourne, Australia
| | - S Chen
- Center for Cancer Prevention and Translational Genomics, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, USA
| | - W Elatre
- Department of Pathology, Norris Comprehensive Cancer Center, Keck School of Medicine, University of Southern California, USA
| | - B Gilks
- British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
| | - T Nazeran
- British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada
| | - M Volchek
- Anatomical Pathology, Royal Women's Hospital, Parkville, Australia
| | - R C Bentley
- Department of Pathology, Duke University Hospital, Durham, USA
| | - C Wang
- Department of Health Science Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, USA
| | - D S Chiu
- British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada
| | - S Kommoss
- Department of Women's Health, Tuebingen University Hospital, Tuebingen, Germany
| | - S C Y Leung
- British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada
| | - J Senz
- British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada
| | - A Lum
- British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada
| | - V Chow
- British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada
| | - H Sudderuddin
- British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada
| | - R Mackenzie
- British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada
| | - J George
- The Jackson Laboratory for Genomic Medicine, Farmington, USA
| | - S Fereday
- Peter MacCallum Cancer Center, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia
| | - J Hendley
- Peter MacCallum Cancer Center, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia
| | - N Traficante
- Peter MacCallum Cancer Center, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia
| | - H Steed
- Department of Obstetrics and Gynecology, Division of Gynecologic Oncology, Royal Alexandra Hospital, Edmonton, Canada
| | - J M Koziak
- Alberta Health Services-Cancer Care, Calgary, Canada
| | - M Köbel
- Department of Pathology and Laboratory Medicine, University of Calgary, Foothills Medical Center, Calgary, Canada
| | - I A McNeish
- Division of Cancer and Ovarian Cancer Action Research Centre, Department Surgery & Cancer, Imperial College London, London, UK; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
| | - T Goranova
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK
| | - D Ennis
- Division of Cancer and Ovarian Cancer Action Research Centre, Department Surgery & Cancer, Imperial College London, London, UK; Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
| | - G Macintyre
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK
| | - D Silva De Silva
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK
| | - T Ramón Y Cajal
- Medical Oncology Service, Hospital Sant Pau, Barcelona, Spain
| | - J García-Donas
- HM Hospitales D Centro Integral Oncológico HM Clara Campal, Madrid, Spain
| | - S Hernando Polo
- Medical Oncology Service, Hospital Universitario Funcacion Alcorcon, Alcorcón, Spain
| | - G C Rodriguez
- Division of Gynecologic Oncology, NorthShore University HealthSystem, University of Chicago, Evanston, USA
| | - K L Cushing-Haugen
- Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, USA
| | - H R Harris
- Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, USA; Department of Epidemiology, University of Washington, Seattle, USA
| | - C S Greene
- Department of Systems Pharmacology and Translational Therapeutics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, USA
| | - R A Zelaya
- Department of Genetics, Geisel School of Medicine at Dartmouth, Hanover, USA
| | - S Behrens
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - R T Fortner
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany
| | - P Sinn
- Department of Pathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany
| | - E Herpel
- Department of Pathology, Institute of Pathology, University Hospital Heidelberg, Heidelberg, Germany; National Center for Tumor Diseases, University Hospital and German Cancer Research Center, Heidelberg, Germany
| | - J Lester
- David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, USA; Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, USA
| | - J Lubiński
- Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - O Oszurek
- Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - A Tołoczko
- Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - C Cybulski
- Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - J Menkiszak
- Department of Gynecological Surgery and Gynecological Oncology of Adults and Adolescents, Pomeranian Medical University, Szczecin, Poland
| | - C L Pearce
- Department of Epidemiology, University of Michigan School of Public Health, Ann Arbor, USA; Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, USA
| | - M C Pike
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California Norris Comprehensive Cancer Center, Los Angeles, USA; Department of Epidemiology and Biostatistics, Memorial Sloan-Kettering Cancer Center, New York, USA
| | - C Tseng
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, USA
| | - J Alsop
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
| | - V Rhenius
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
| | - H Song
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK
| | - M Jimenez-Linan
- Department of Pathology, Addenbrooke's Hospital NHS Trust, Cambridge, UK
| | - A M Piskorz
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK
| | - A Gentry-Maharaj
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, London, UK
| | - C Karpinskyj
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, London, UK
| | - M Widschwendter
- Department of Women's Cancer, Institute for Women's Health, University College London, London, UK
| | - N Singh
- Department of Pathology, Barts Health National Health Service Trust, London, UK
| | - C J Kennedy
- Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia; Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia
| | - R Sharma
- Pathology West ICPMR Westmead, Westmead Hospital, The University of Sydney, Sydney, Australia; University of Western Sydney at Westmead Hospital, Sydney, Australia
| | - P R Harnett
- Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia; The Crown Princess Mary Cancer Centre Westmead, Sydney-West Cancer Network, Westmead Hospital, Sydney, Australia
| | - B Gao
- Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia; The Crown Princess Mary Cancer Centre Westmead, Sydney-West Cancer Network, Westmead Hospital, Sydney, Australia
| | - S E Johnatty
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - R Sayer
- Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia
| | - J Boros
- Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia; Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia
| | - S J Winham
- Department of Health Science Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, USA
| | - G L Keeney
- Department of Laboratory Medicine and Pathology, Division of Anatomic Pathology, Mayo Clinic, Rochester, USA
| | - S H Kaufmann
- Department of Oncology, Mayo Clinic, Rochester, USA; Department of Molecular Pharmacology and Experimental Therapeutics, Mayo Clinic, Rochester, USA
| | - M C Larson
- Department of Health Science Research, Division of Biomedical Statistics and Informatics, Mayo Clinic, Rochester, USA
| | - H Luk
- Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, USA
| | - B Y Hernandez
- Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, USA
| | - P J Thompson
- Samuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Cedars-Sinai Medical Center, Los Angeles, USA
| | - L R Wilkens
- Cancer Epidemiology Program, University of Hawaii Cancer Center, Honolulu, USA
| | - M E Carney
- John A. Burns School of Medicine, Department of Obstetrics and Gynecology, University of Hawaii, Honolulu, USA
| | - B Trabert
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, USA
| | - J Lissowska
- Department of Cancer Epidemiology and Prevention, M Sklodowska Curie National Research Institute of Oncology, Warsaw, Poland
| | - L Brinton
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, USA
| | - M E Sherman
- Department of Health Sciences Research, Mayo Clinic College of Medicine, Jacksonville, USA
| | - C Bodelon
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, USA
| | - S Hinsley
- Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
| | - L A Lewsley
- Cancer Research UK Clinical Trials Unit, Institute of Cancer Sciences, University of Glasgow, Glasgow, UK
| | - R Glasspool
- Department of Medical Oncology, Beatson West of Scotland Cancer Centre and University of Glasgow, Glasgow, UK
| | - S N Banerjee
- The Royal Marsden NHS Foundation Trust and Institute of Cancer Research, London, UK
| | - E A Stronach
- Division of Cancer and Ovarian Cancer Action Research Centre, Department Surgery & Cancer, Imperial College London, London, UK
| | - P Haluska
- Department of Oncology, Mayo Clinic, Rochester, USA
| | - I Ray-Coquard
- Centre Leon Berard and University Claude Bernard Lyon 1, Lyon, France
| | - S Mahner
- Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Munich, Germany
| | - B Winterhoff
- Department of Obstetrics, Gynecology and Women's Health, University of Minnesota, Minneapolis, USA
| | - D Slamon
- David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, USA
| | - D A Levine
- Gynecology Service, Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, USA; Gynecologic Oncology, Laura and Isaac Pearlmutter Cancer Center, NYU Langone Medical Center, New York, USA
| | - L E Kelemen
- Hollings Cancer Center and Department of Public Health Sciences, Medical University of South Carolina, Charleston, USA
| | - J Benitez
- Centro de Investigación en Red de Enfermedades Raras (CIBERER), Madrid, Spain; Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain
| | - J Chang-Claude
- Division of Cancer Epidemiology, German Cancer Research Center (DKFZ), Heidelberg, Germany; Cancer Epidemiology Group, University Cancer Center Hamburg (UCCH), University Medical Center Hamburg-Eppendorf, Hamburg, Germany
| | - J Gronwald
- Department of Genetics and Pathology, Pomeranian Medical University, Szczecin, Poland
| | - A H Wu
- Department of Preventive Medicine, Keck School of Medicine, University of Southern California, Los Angeles, USA
| | - U Menon
- MRC Clinical Trials Unit at UCL, Institute of Clinical Trials & Methodology, University College London, London, UK
| | - M T Goodman
- Samuel Oschin Comprehensive Cancer Institute, Cancer Prevention and Genetics Program, Cedars-Sinai Medical Center, Los Angeles, USA
| | - J M Schildkraut
- Department of Epidemiology, Rollins School of Public Health, Emory University, Atlanta, USA
| | - N Wentzensen
- Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, USA
| | - R Brown
- Division of Cancer and Ovarian Cancer Action Research Centre, Department of Surgery and Cancer, Imperial College London, London, UK
| | - A Berchuck
- Department of Gynecologic Oncology, Duke University Hospital, Durham, USA
| | - G Chenevix-Trench
- Department of Genetics and Computational Biology, QIMR Berghofer Medical Research Institute, Brisbane, Queensland, Australia
| | - A deFazio
- Centre for Cancer Research, The Westmead Institute for Medical Research, The University of Sydney, Sydney, Australia; Department of Gynaecological Oncology, Westmead Hospital, Sydney, Australia
| | - S A Gayther
- Center for Bioinformatics and Functional Genomics and the Cedars Sinai Genomics Core, Cedars-Sinai Medical Center, Los Angeles, USA
| | - M J García
- Human Cancer Genetics Programme, Spanish National Cancer Research Centre (CNIO), Madrid, Spain; Biomedical Network on Rare Diseases (CIBERER), Madrid, Spain
| | - M J Henderson
- Children's Cancer Institute, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, Australia
| | - M A Rossing
- Program in Epidemiology, Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, USA; Department of Epidemiology, University of Washington, Seattle, USA
| | - A Beeghly-Fadiel
- Division of Epidemiology, Department of Medicine, Vanderbilt Epidemiology Center, Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, USA
| | - P A Fasching
- David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, USA; Department of Gynecology and Obstetrics, Comprehensive Cancer Center ER-EMN, University Hospital Erlangen, Friedrich-Alexander-University Erlangen-Nuremberg, Erlangen, Germany
| | - S Orsulic
- David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, USA; Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, USA
| | - B Y Karlan
- David Geffen School of Medicine, Department of Obstetrics and Gynecology, University of California at Los Angeles, Los Angeles, USA; Women's Cancer Program at the Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, Los Angeles, USA
| | - G E Konecny
- David Geffen School of Medicine, Department of Medicine Division of Hematology and Oncology, University of California at Los Angeles, Los Angeles, USA
| | - D G Huntsman
- British Columbia's Ovarian Cancer Research (OVCARE) Program, BC Cancer, Vancouver General Hospital, and University of British Columbia, Vancouver, Canada; Department of Pathology and Laboratory Medicine, University of British Columbia, Vancouver, Canada; Department of Obstetrics and Gynecology, University of British Columbia, Vancouver, Canada; Department of Molecular Oncology, BC Cancer Research Centre, Vancouver, Canada
| | - D D Bowtell
- Peter MacCallum Cancer Center, Melbourne, Australia; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Parkville, Australia
| | - J D Brenton
- Cancer Research UK Cambridge Institute, University of Cambridge, Cambridge, UK
| | - J A Doherty
- Huntsman Cancer Institute, Department of Population Health Sciences, University of Utah, Salt Lake City, USA
| | - P D P Pharoah
- Centre for Cancer Genetic Epidemiology, Department of Oncology, University of Cambridge, Cambridge, UK; Centre for Cancer Genetic Epidemiology, Department of Public Health and Primary Care, University of Cambridge, Cambridge, UK
| | - S J Ramus
- School of Women's and Children's Health, Faculty of Medicine, University of NSW Sydney, Sydney, Australia; Adult Cancer Program, Lowy Cancer Research Centre, University of NSW Sydney, Sydney, Australia.
| |
Collapse
|